» kinderkrebsinfo.de » Health professionals » Clinical Trials » Literature on clinical trials  · 

Literature on clinical trials

Author: Julia Dobke, erstellt 2006/03/07, Editor: Prof. Dr. med. Ursula Creutzig, English Translation: Dr. med. Gesche Tallen, Last modification: 2011/05/23

Here you will find various relevant publications on clinical trials in paediatric oncology/haematology listed according to the name of the study or the type of cancer, respectively.

Leukaemias

Literature on trial ALL-BFM

Search PubMed for recently published articles (external information service)
  1. Schrey D, Borghorst S, Lanvers-Kaminsky C, Hempel G, Gerss J, Möricke A, Schrappe M, Boos J: Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatric blood & cancer 2010, 54: 952 [PMID: 20108339]
  2. Hempel G, Müller HJ, Lanvers-Kaminsky C, Würthwein G, Hoppe A, Boos J: A population pharmacokinetic model for pegylated-asparaginase in children. British journal of haematology 2010, 148: 119 [PMID: 19821822]
  3. Pichler H, Möricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, König M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grümayer R, Attarbaschi A, Berlin-Frankfurt-Münster (BFM) Study Group: Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. British journal of haematology 2010, 149: 93 [PMID: 20067563]
  4. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115: 3206 [PMID: 20154213]
  5. Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, Schrauder A, Moericke A, Izraeli S, Akasaka T, Dyer MJ, Siebert R, Schrappe M, Stanulla M: Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, [PMID: 20378752]
  6. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia : 2010, 24: 265 [PMID: 20010625]
  7. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ, European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL),International Berlin-Frankfurt-Münster Study Group (I-BFM-SG): Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24: 521 [PMID: 20033054]
  8. Krieger D, Moericke A, Oschlies I, Zimmermann M, Schrappe M, Reiter A, Burkhardt B: Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica 2010, 95: 158 [PMID: 19586936]
  9. Schrappe M, Nachman J, Hunger S, Schmiegelow K, Conter V, Masera G, Pieters R, Pui CH: 'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'. Leukemia 2010, 24: 253 [PMID: 20145664]
  10. Staege MS, Körholz D: New treatment strategies for Hodgkin's lymphoma. Leukemia research 2009, 33: 886 [PMID: 19233468]
  11. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, Biondi A, Schrappe M, Ludwig WD, Karawajew L, AIEOP-BFM-FCM-MRD-Study Group: Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009, 23: 528 [PMID: 19020543]
  12. Stanulla M, Schaeffeler E, Möricke A, Coulthard SA, Cario G, Schrauder A, Kaatsch P, Dördelmann M, Welte K, Zimmermann M, Reiter A, Eichelbaum M, Riehm H, Schrappe M, Schwab M: Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. Blood 2009, 114: 1314 [PMID: 19535798]
  13. Kidas E, Möricke A, Beier R, Welte K, Schrappe M, Stanulla M, Grigull L: Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study. International journal of hematology 2009, 89: 584 [PMID: 19353239]
  14. Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A, Werft W, Breit S, Liu S, Engel F, Wittmann A, Zimmermann M, Stanulla M, Schrappe M, Ludwig WD, Bartram CR, Radlwimmer B, Muckenthaler MU, Lichter P, Kulozik AE: High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16. 1 as a genomic marker for unfavorable early treatment response. Blood 2009, 114: 1053 [PMID: 19406988]
  15. Biondi A, Baruchel A, Hunger S, Masera G, Schmiegelow K, Schrappe M, Pui CH: The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia 2009, 23: 2318 [PMID: 19890375]
  16. Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ, Interfant-99 Study Group: Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009, 23: 1073 [PMID: 19212338]
  17. Schrappe M: Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. Radiation protection dosimetry 2008, 132: 130 [PMID: 19017727]
  18. Cario G, Fetz A, Bretscher C, Möricke A, Schrauder A, Stanulla M, Schrappe M: Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia. Annals of hematology 2008, 87: 709 [PMID: 18521602]
  19. Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA: Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Münster (ALL-BFM) trials. Journal of clinical oncology 2008, 26: 3046 [PMID: 18565891]
  20. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR, International BFM Study Group (I-BFM-SG): Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008, 22: 771 [PMID: 18239620]
  21. Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, Zimmermann M, Strauch K, Ludwig WD, Schrappe M, Reiter A: Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leukemia & lymphoma 2008, 49: 451 [PMID: 18297521]
  22. Teuffel O, Stanulla M, Cario G, Ludwig WD, Rottgers S, Schafer BW, Zimmermann M, Schrappe M, Niggli FK: Anemia and survival in childhood acute lymphoblastic leukemia. Haematologica 2008, 93: 1652 [PMID: 18815194]
  23. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German-Austrian-Swiss ALL-BFM Study Group: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008, 111: 4477 [PMID: 18285545]
  24. Mann G, Cazzaniga G, van der Velden VH, Flohr T, Csinady E, Paganin M, Schrauder A, Dohnal AM, Schrappe M, Biondi A, Gadner H, van Dongen JJ, Panzer-Grümayer ER: Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease? Leukemia 2007, 21: 642 [PMID: 17287854]
  25. Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Möricke A, Zimmermann M, Schrauder A, Karawajew L, Ludwig WD, Welte K, Schünemann HJ, Schlegelberger B, Schrappe M, Stanulla M: High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. Journal of clinical oncology 2007, 25: 4813 [PMID: 17947730]
  26. Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E, Gadner H, Stary J, Benoit Y, Zimmermann M, Reiter A, Riehm H, Masera G, Schrappe M: Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007, 369: 123 [PMID: 17223475]
  27. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370: 240 [PMID: 17658395]
  28. Stanulla M, Cario G, Meissner B, Schrauder A, Möricke A, Riehm H, Schrappe M: Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group. Blood cells, molecules & diseases 2007, 39: 160 [PMID: 17532236]
  29. Bürger B, Zimmermann M, Mann G, Kühl J, Loning L, Riehm H, Reiter A, Schrappe M: Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21: 184 [PMID: 12525508]
  30. Schrappe M, Beier R, Burger B: New treatment strategies in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002, 15: 729 [PMID: 12617873]
  31. Lauten M, Stanulla M, Zimmermann M, Welte K, Riehm H, Schrappe M: Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Pädiatr 2001, 213: 169 [PMID: 11528550]
  32. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W, Henze G, Gadner H, Odenwald E, Riehm H: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000, 14: 2205 [PMID: 11187912]
  33. Schrappe M, Reiter A, Ludwig W, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy. Blood 2000, 95: 3310 [PMID: 10828010]
  34. Stanulla M, Schrappe M, Brechlin A, Zimmermann M, Welte K: Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2000, 95: 1222 [PMID: 10666194]
  35. van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352: 1731 [PMID: 9848348]

Literature on ALL-relapse

Search PubMed for recently published articles (external information service)
  1. von Stackelberg A, Völzke E, Kühl JS, Seeger K, Schrauder A, Escherich G, Henze G, Tallen G, for the ALL-REZ BFM Study Group: Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group. European journal of cancer 2011, 47: 90 [PMID: 20970323]
  2. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A: Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90. Journal of clinical oncology 2010, 28: 2339 [PMID: 20385996]
  3. Shalapour S, Eckert C, Seeger K, Pfau M, Prada J, Henze G, Blankenstein T, Kammertoens T: Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. Journal of molecular medicine 2010, 88: 249 [PMID: 20155409]
  4. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A: Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2010 Oct 14; [PMID: 20944674]
  5. Bastian L, Einsiedel HG, Henze G, Seeger K, Shalapour S: The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells. Leukemia 2010 Nov 12; [PMID: 21072050]
  6. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of clinical oncology 2009, 27: 377 [PMID: 19064980]
  7. von Stackelberg A, Hartmann R, Bührer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G, ALL-REZ BFM Study Group: High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood 2008, 111: 2573 [PMID: 18089849]
  8. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. European journal of cancer (Oxford, England : 1990) 2008, 44: 257 [PMID: 17981026]
  9. Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hahlen K, Göbel U, Klingebiel T, Ludwig WD, Henze G: Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. Journal of clinical oncology 2005, 23: 7942 [PMID: 16258094]
  10. Wellmann S, Moderegger E, Zelmer A, Bettkober M, von Stackelberg A, Henze G, Seeger K: FLT3 mutations in childhood acute lymphoblastic leukemia at first relapse. Leukemia 2005, 19: 467 [PMID: 15674414]
  11. Wagner-Bohn A, Henze G, von Stackelberg A, Boos J: Phase II study of gemcitabine in children with relapsed leukemia. Pediatric blood & cancer 2006, 46: 262 [PMID: 16331664]
  12. Nenning UC, Eckert C, Wellmann S, Barth A, Henze G, Seeger K: Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. Journal of the National Cancer Institute 2005, 97: 1091-2; author reply 1093 [PMID: 16030311]
  13. Henze G: 20 Jahre Studien zur Behandlung von Kindern mit Rezidiv einer akuten lymphoblastischen Leukämie (ALL-REZ BFM). WIR Informationsschrift der Aktion für krebskranke Kinder e.V. (Bonn) 2004, 3: 13 [URI: http://www.kinderkrebsstiftung.de/fileadmin/KKS/files/zeitschriftWIR/2004_3/ALL-REZ.pdf]

Literature on stem cell transplantation for ALL treatment

Search PubMed for recently published articles (external information service)
  1. Wachowiak J, Sykora KW, Cornish J, Chybicka A, Kowalczyk JR, Gorczyńska E, Choma M, Grund G, Peters C: Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant 2011, Epub ahead of print [PMID: 21297673]
  2. Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, De Rossi G, Felice M, Lausen B, Leblanc T, Szczepanski T, Ferster A, Janka-Schaub G, Rubnitz J, Silverman LB, Stary J, Campbell M, Li CK, Suppiah R, Biondi A, Vora A, Valsecchi MG, Pieters R: Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukaemia: results from the Interfant-99 Study. Blood 2010 Jun 30; [Epub ahead of print] [PMID: 20592248]
  3. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Fernández-Viña M, Geraghty DE, Holdsworth R, Hurley CK, Lau M, Lee KW, Mach B, Maiers M, Mayr WR, Müller CR, Parham P, Petersdorf EW, Sasazuki T, Strominger JL, Svejgaard A, Terasaki PI, Tiercy JM, Trowsdale J: An update to HLA Nomenclature, 2010. Bone marrow transplantation 2010, 45: 846 [PMID: 20348972]
  4. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G, Rocha V, Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT): Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010, 115: 3437 [PMID: 20040760]
  5. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of clinical oncology 2009, 27: 377 [PMID: 19064980]
  6. Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C, ALL-BFM Study Group, EBMT PD WP, I-BFM Study Group: Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone marrow transplantation 2008, 41 Suppl 2:S71 [PMID: 18545248]
  7. Balduzzi A, De Lorenzo P, Schrauder A, Conter V, Uderzo C, Peters C, Klingebiel T, Stary J, Felice MS, Magyarosy E, Schrappe M, Dini G, Gadner H, Valsecchi MG: Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica 2008, 93: 925 [PMID: 18413892]
  8. Kircher B, Niederwieser D, Gächter A, Lindner B, Mitterschiffthaler A, Urban C, Greinix H, Peters C, Lätzer K, Gastl G, Nachbaur D: T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation. International journal of laboratory hematology 2008, 30: 499 [PMID: 18522713]
  9. Lanino E, Sacchi N, Peters C, Giardino S, Rocha V, Dini G, EBMT Paediatric, Acute Leukemia Working Parties, Eurocord: Strategies of the donor search for children with second CR ALL lacking a matched sibling donor. Bone marrow transplantation 2008, 41 Suppl 2:S75 [PMID: 18545249]
  10. Dini G, Locatelli F, Peters C, Wachowiak J, EBMT Paediatric Diseases: Proceedings of the 6th Meeting of the EBMT Paediatric Diseases Working Party and 1st Meeting of the EBMT Paediatric Nurses. Introduction. Bone marrow transplantation 2008, 42 Suppl 2:S1 [PMID: 18978734]
  11. Meissner B, Borkhardt A, Dilloo D, Fuchs D, Friedrich W, Handgretinger R, Peters C, Schrauder A, Schuster FR, Vormoor J, Maecker B, Sykora KW, Zintl F, Welte K, Sauer M: Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. Bone marrow transplantation 2007, 40: 945 [PMID: 17768387]
  12. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, Locatelli F, Fischer A, Egeler RM, Or R, Peters C, Ortega J, Veys P, Bordigoni P, Iori AP, Niethammer D, Rocha V, Dini G, Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation: Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone marrow transplantation 2007, 39: 89 [PMID: 17213848]
  13. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M: Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. Journal of clinical oncology 2006, 24: 5742 [PMID: 17179108]
  14. Seidel MG, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Pötschger U, Rosenmayr A, Fischer G, Gadner H, Peters C: In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Haematologica 2005, 90: 1405 [PMID: 16219578]
  15. Peters C, Schrauder A, Schrappe M, von Stackelberg A, Stary J, Yaniv I, Gadner H, Klingebiel T, BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT: Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone marrow transplantation 2005, 35 Suppl 1:S9 [PMID: 15812540]
  16. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, Stary J, Felice MS, Magyarosy E, Conter V, Reiter A, Messina C, Gadner H, Schrappe M: Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005, 366: 635 [PMID: 16112299]
  17. Matthes-Martin S, Lion T, Aberle SW, Fritsch G, Lawitschka A, Bittner B, Frommlet F, Gadner H, Peters C: Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone marrow transplantation 2003, 31: 803 [PMID: 12732888]

Literature on trial Co-ALL

Search PubMed for recently published articles (external information service)
  1. Escherich G, Troeger AF, Göbel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, Zur Stadt U, Kazemir K, Pieters R, Horstmann M, Denboer ML, Janka-Schaub G: The long-term impact of in vitro drug sensitivity testing on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 2011, Epub ahead of print [PMID: 21330320]
  2. Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE, COALL study group: Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia : 2010, 24: 298 [PMID: 20016530]
  3. Krappmann P, Paulides M, Stöhr W, Ittner E, Plattig B, Nickel P, Lackner H, Schrappe M, Janka G, Beck JD, Langer T: Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up. Pediatric hematology and oncology 2007, 24: 101 [PMID: 17454775]
  4. Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE: Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klinische Padiatrie 2007, 219: 134 [PMID: 17525906]
  5. Graubner UB, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G, Janka GE: Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatric blood & cancer 2008, 50: 259 [PMID: 17635005]
  6. van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P, Poulsen TS, den Boer ML, Horstmann M, Kamps WA, Veerman AJ, van Wering ER, van Noesel MM, Pieters R: The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica 2006, 91: 1212 [PMID: 16956820]
  7. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, Pieters R: Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. Clinical cancer research 2005, 11: 2974 [PMID: 15837750]
  8. Khalil MN, Erb N, Khalil PN, Escherich G, Janka-Schaub GE: Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005, 821: 105 [PMID: 15897017]
  9. Stams WA, den Boer ML, Holleman A, Appel IM, Beverloo HB, van Wering ER, Janka-Schaub GE, Evans WE, Pieters R: Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005, 105: 4223 [PMID: 15718422]
  10. Holleman A, den Boer ML, Kazemier KM, Beverloo HB, von Bergh AR, Janka-Schaub GE, Pieters R: Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood 2005, 106: 1817 [PMID: 15899912]
  11. Zur Stadt U, Isbarn H, Schneppenheim R, Kabisch H: DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach. International journal of oncology 2005, 27: 547 [PMID: 16010438]
  12. Lugthart S, Cheok MH, den Boer ML, Yang W, Holleman A, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE: Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer cell 2005, 7: 375 [PMID: 15837626]
  13. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. The New England journal of medicine 2004, 351: 533 [PMID: 15295046]
  14. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, Slater RM, Harbott J, den Boer ML, Ludwig WD, Haas OA, Janka-Schaub GE, Pieters R: In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004, 18: 521 [PMID: 14712291]

Literature on AML

Search PubMed for recently published articles (external information service)
  1. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, von Neuhoff C, Sander A, Schrauder A, von Stackelberg A, Ritter J, Starý J, Reinhardt D: CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer 2011, [Epub ahead of print] [PMID: 21480469]
  2. Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ, International BFM Study Group on Paediatric AML: Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. British journal of haematology 2010, 148: 768 [PMID: 19995399]
  3. Balgobind BV, Hollink IH, Reinhardt D, van Wering ER, de Graaf SS, Baruchel A, Stary J, Beverloo HB, de Greef GE, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM: Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. European journal of cancer 2010, [PMID: 20233657]
  4. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA, Dworzak MN, Creutzig U: Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98. Journal of clinical oncology 2010, 28: 2682 [PMID: 20439630]
  5. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ: A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010, [PMID: 20538803]
  6. Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B, Lakomek M, Bourquin JP, Stary J, Reinhardt D: Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. British journal of haematology 2010, 149: 399 [PMID: 20230404]
  7. Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D, Kaspers GJ, Creutzig U: Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010, [PMID: 20535146]
  8. Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, Zwaan CM, Reinhardt K, Hollink IH, Klusmann JH, Lehrnbecher T, Roettgers S, Stary J, Dworzak M, Welte K, Creutzig U, Reinhardt D: Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. Journal of clinical oncology 2010, 28: 2591 [PMID: 20406937]
  9. Goemans BF, Zwaan CM, Cloos J, de Lange D, Loonen AH, Reinhardt D, Hählen K, Gibson BE, Creutzig U, Kaspers GJ: FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leukemia research 2010, [PMID: 20435347]
  10. Klusmann JH, Li Z, Böhmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D: miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes & development 2010, 24: 478 [PMID: 20194440]
  11. Zwaan CM, Reinhardt D, Hitzler J, Vyas P: Acute leukemias in children with Down syndrome. Hematology/oncology clinics of North America 2010, 24: 19 [PMID: 20113894]
  12. Gerr H, Zimmermann M, Schrappe M, Dworzak M, Ludwig WD, Bradtke J, Moericke A, Schabath R, Creutzig U, Reinhardt D: Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. British journal of haematology 2010, 149: 84 [PMID: 20085575]
  13. Meyer LH, Queudeville M, Eckhoff SM, Creutzig U, Reinhardt D, Karawajew L, Ludwig WD, Stahnke K, Debatin KM: Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. Blood 2008, 111: 2899 [PMID: 18083847]
  14. Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J, Kaspers GJ, de Graaf SS, Harbott J, Creutzig U, Reinhardt D, van den Heuvel-Eibrink MM, Thiede C: Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009, 23: 262 [PMID: 19020547]
  15. Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, Schlenk RF: Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 2008, 112: 562 [PMID: 18076087]
  16. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, Reinhardt D: Treatment and prognostic impact of transient leukemia in neonates with Down's syndrome. Blood 2008, 111: 2991 [PMID: 18182574]
  17. Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Haas OA, Harbott J, Harrison CJ, Heerema NA, van den Heuvel-Eibrink MM, Kaspers GJ, Locatelli F, Noellke P, Polychronopoulou S, Ravindranath Y, Razzouk B, Reinhardt D, Savva NN, Stark B, Suciu S, Tsukimoto I, Webb DK, Wojcik D, Woods WG, Zimmermann M, Niemeyer CM, Raimondi SC: Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 2007, 109: 4641 [PMID: 17299091]
  18. Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U: Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood 2007, 109: 936 [PMID: 17008536]
  19. Creutzig U, Diekamp S, Zimmermann M, Reinhardt D: Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatric blood & cancer 2007, 48: 651 [PMID: 17183582]
  20. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D: Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Journal of clinical oncology 2006, 24: 4499 [PMID: 16983120]
  21. Reinhardt D, Ritter J: Reaktive Veränderungen des Blutbildes und des Knochenmarks. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J, editors. Pädiatrische Hämatologie und Onkologie Berlin, Heidelberg, New York: Springer Verlag, 2006, 309
  22. Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, Zimmermann M, Reinhardt D: Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. Journal of clinical oncology 2006, 24: 3686 [PMID: 16877738]
  23. Reinhardt D, Ritter J: Klassifikation der Leukämien und malignen Lymphome. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J, editors. Pädiatrische Hämatologie und Onkologie Berlin, Heidelberg, New York: Springer Verlag, 2006, 647 [ISBN: 3540037020
  24. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jürgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G: Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005, 19: 2030 [PMID: 16304570]
  25. Classen CF, Teigler-Schlegel A, Rottgers S, Reinhardt D, Dohner K, Debatin KM: AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid. Annals of hematology 2005, 84: 774 [PMID: 16044313]
  26. Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hahlen K, Reinhardt D, Creutzig U, Heinrich MC, Kaspers GJ: In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005, 106: 3532 [PMID: 16051737]
  27. Lehrnbecher T, Bernig T, Hanisch M, Koehl U, Behl M, Reinhardt D, Creutzig U, Klingebiel T, Chanock SJ, Schwabe D: Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005, 19: 1745 [PMID: 16107886]
  28. Langebrake C, Creutzig U, Reinhardt D: Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klinische Padiatrie 2005, 217: 126 [PMID: 15858703]
  29. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19: 1536 [PMID: 16015387]
  30. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U, Reinhardt D: Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. The Journal of pharmacology and experimental therapeutics 2005, 312: 346 [PMID: 15501994]
  31. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U, Reinhardt D: Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry. Part B, Clinical cytometry 2005, 63: 1 [PMID: 15624201]
  32. Hubeek I, Peters GJ, Broekhuizen AJ, Talianidis I, Sigmond J, Gibson BE, Creutzig U, Giaccone G, Kaspers GJ: Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. Journal of clinical pathology 2005, 58: 695 [PMID: 15976334]
  33. Reinhardt D, Diekamp S, Langebrake C, Ritter J, Stary J, Dworzak M, Schrauder A, Zimmermann M, Fleischhack G, Ludwig WD, Harbott J, Creutzig U: Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia 2005, 19: 1495 [PMID: 15920489]
  34. Goemans BF, Zwaan CM, Martinelli S, Harrell P, de Lange D, Carta C, Reinhardt D, Hahlen K, Creutzig U, Tartaglia M, Heinrich MC, Kaspers GJ: Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia. British journal of haematology 2005, 130: 801 [PMID: 16115145]
  35. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, Kaspers GL, Lessard M, Michaux L, Vyas P, van Wering E, Zwaan CM, Golub TR, Orkin SH: Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America 2006, 103: 3339 [PMID: 16492768]
  36. Cloos J, Zwaan CM, Corthals SL, Goemans BF, Waisfisz Q, Creutzig U, Reinhardt D, Hählen K, Kaspers GJL: FLT3/Internal Tandem Duplication in Paired Presentation and Relapse Pediatric AML Samples. Blood 2004, 104[11], 30a.

Literature on CML

Search PubMed for recently published articles (external information service)
  1. Schmid H, Jaeger B, Lohse J, Suttorp M: Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009, 94: 1177 [PMID: 19546438]

Myelodysplastic syndrome (MDS)

Literature on trial EWOG-MDS

Search PubMed for recently published articles (external information service)
  1. Strahm B, Nöllke P, Zecca M, Korthof ET, Bierings M, Furlan I, Sedlacek P, Chybicka A, Schmugge M, Bordon V, Peters C, O'Marcaigh A, de Heredia CD, Bergstraesser E, Moerloose BD, van den Heuvel-Eibrink MM, Starý J, Trebo M, Wojcik D, Niemeyer CM, Locatelli F, EWOG-MDS study group: Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011, 25: 455 [PMID: 21212791]
  2. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML: Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010, 42: 794 [PMID: 20694012]
  3. Karow A, Baumann I, Niemeyer CM: Morphologic differential diagnosis of juvenile myelomonocytic leukemia--pitfalls apart from viral infection. Journal of pediatric hematology/oncology 2009, 31: 380 [PMID: 19415027]
  4. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM: Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009, 114: 1859 [PMID: 19571318]
  5. de Vries AC, Bredius RG, Lankester AC, Bierings M, Trebo M, Sedlacek P, Niemeyer CM, Zecca M, Locatelli F, van den Heuvel-Eibrink MM: HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia. Haematologica 2009, 94: 302 [PMID: 19109215]
  6. Furlan I, Batz C, Flotho C, Mohr B, Lübbert M, Suttorp M, Niemeyer CM: Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood 2009, 113: 2867 [PMID: 19299654]
  7. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM: Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Annals of hematology 2008, 87: 691 [PMID: 18575866]
  8. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstrasser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML: The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005, 106: 2183 [PMID: 15928039]
  9. Yoshimi A, Niemeyer CM, Bohmer V, Duffner U, Strahm B, Kreyenberg H, Dilloo D, Zintl F, Claviez A, Wossmann W, Kremens B, Holter W, Niethammer D, Beck JF, Kontny U, Nollke P, Klingebiel T, Bader P: Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. British journal of haematology 2005, 129: 542 [PMID: 15877738]
  10. Bader P, Niemeyer C, Willasch A, Kreyenberg H, Strahm B, Kremens B, Gruhn B, Dilloo D, Vormoor J, Lang P, Niethammer D, Klingebiel T, Beck JF: Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. British journal of haematology 2005, 128: 649 [PMID: 15725087]
  11. Yoshimi A, Bader P, Matthes-Martin S, Stary J, Sedlacek P, Duffner U, Klingebiel T, Dilloo D, Holter W, Zintl F, Kremens B, Sykora KW, Urban C, Hasle H, Korthof E, Revesz T, Fischer A, Nollke P, Locatelli F, Niemeyer CM, European Working Group of MDS in Childhood (EWOG-MDS): Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005, 19: 971 [PMID: 15800672]
  12. Cantu Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I, European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS): Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Annals of hematology 2005, 84: 429 [PMID: 15838669]
  13. Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, Bonfim CS, Bader P, Dilloo D, Stary J, Fischer A, Revesz T, Fuhrer M, Hasle H, Trebo M, van den Heuvel-Eibrink MM, Fenu S, Strahm B, Giorgiani G, Bonora MR, Duffner U, Niemeyer CM, European Working Group on Childhood MDS, European Blood and Marrow Transplantation Group: Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005, 105: 410 [PMID: 15353481]
  14. Kratz CP, Rogge T, Kopp M, Baumann I, Niemeyer CM: Myelodysplastic features in an infant with cystic fibrosis presenting with anaemia, oedema and failure to thrive. European journal of pediatrics 2005, 164: 56 [PMID: 15517378]
  15. Bader P, Niemeyer C, Weber G, Coliva T, Rossi V, Kreyenberg H, Gerecke A, Biondi A: WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? European journal of haematology 2004, 73: 25 [PMID: 15182334]
  16. Hasle H, Baumann I, Bergstrasser E, Fenu S, Fischer A, Kardos G, Kerndrup G, Locatelli F, Rogge T, Schultz KR, Stary J, Trebo M, van den Heuvel-Eibrink MM, Harbott J, Nollke P, Niemeyer CM, European Working Group on childhood MDS: The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004, 18: 2008 [PMID: 15496981]
  17. Dolman KM, Revesz T, Niemeyer CM, van Wering ER, de Saint Basile G, Canninga M, Bierings MB, Wulffraat NM: Myelodysplastic features in Griscelli syndrome. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2004, 26: 275 [PMID: 15111776]
  18. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, Head DR: A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003, 17: 277 [PMID: 12592323]
  19. Hammerle K, Shayan P, Niemeyer CM, Flotho C: Expression analysis of alpha-NAC and ANX2 in juvenile myelomonocytic leukemia using SMART polymerase chain reaction and. Cancer genetics and cytogenetics 2003, 142: 149 [PMID: 12699894]
  20. Bader P, Stoll K, Huber S, Geiselhart A, Handgretinger R, Niemeyer C, Einsele H, Schlegel PG, Niethammer D, Beck J, Klingebiel T: Characterization of lineage-specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. British journal of haematology 2000, 108: 761 [PMID: 10792281]

Lymphomas

Literature on Hodgkin-Lymphomas

Search PubMed for recently published articles (external information service)
  1. Kluge R, Körholz D: [Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma. Klinische Padiatrie 2011, [Epub ahead of print] [PMID: 22012607]
  2. Pinkwart C, Stiefel M, Mauz-Körholz C, Körholz D: [Akute Psyschose bei einer jugendlichen Patientin während der Therapie eines nodulären lymphozytenprädominanten Hodgkin-Lymphoms (nLPHL) Stadium IIB]. Klinische Padiatrie 2011, 223: 370 [PMID: 22052634]
  3. Purz S, Mauz-Körholz C, Körholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O, Kranert WT, Weber WA, Haberkorn U, Hundsdörfer P, Ehlert K, Becker M, Rössler J, Kulozik AE, Sabri O, Kluge R: [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, 10; 29: 3523 [PMID: 21825262]
  4. Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D: Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study. Journal of clinical oncology 2010, [PMID: 20625128]
  5. Staege MS, Körholz D: New treatment strategies for Hodgkin's lymphoma. Leukemia research 2009, 33: 886 [PMID: 19233468]
  6. Staege MS, Banning-Eichenseer U, Weissflog G, Volkmer I, Burdach S, Richter G, Mauz-Körholz C, Föll J, Körholz D: Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Experimental hematology 2008, 36: 886 [PMID: 18400362]
  7. Foell JL, Max D, Giersberg C, Körholz D, Staege MS: Sensitivity of Hodgkin's lymphoma cell lines to the cell cycle inhibitor roscovitine. Anticancer research 2008, 28: 887 [PMID: 18507033]
  8. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, Shankar A, Dörffel W, Wallace WH, Schellong G, Robert A, Körholz D, Oberlin O, Hall GW, Landman-Parker J: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007, 110: 179 [PMID: 17526010]
  9. Banning U, Barthel H, Mauz-Körholz C, Kluge R, Körholz D, Sabri O: Effect of drug-induced cytotoxicity on glucose uptake in Hodgkin's lymphoma cells. European journal of haematology 2006, 77: 102 [PMID: 16800842]
  10. Schellong G, Dörffel W, Claviez A, Körholz D, Mann G, Scheel-Walter HG, Bokkerink JP, Riepenhausen M, Luders H, Potter R, Ruhl U, DAL/GPOH: Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. Journal of clinical oncology 2005, 23: 6181 [PMID: 16135485]
  11. Körholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F, Dörffel W, Wickmann L, Papsdorf K, Dieckmann K, Kahn T, Mauz-Korholz C, Dannenberg C, Potter R, Brosteanu O, Schellong G, Sabri O: The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease. Klin Pädiatr 2004, 216: 150 [PMID: 15175959]
  12. Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, Dannenberg C, Hasenclever D, Dörffel W, Sabri O: Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol. Onkologie 2003, 26: 489 [PMID: 14605468]

Literature on Non-Hodgkin-Lymphomas

Search PubMed for recently published articles (external information service)
  1. Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, Brugières L, Le Deley MC, on behalf of European Inter-Group for Childhood, Non-Hodgkin Lymphoma (EICNHL): Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: Report of the ALCL99 randomised trial. Pediatr Blood Cancer 2011, Epub ahead of print [DOI: 10.1002/pbc.22940]
  2. Woessmann W, Zimmermann M, Lenhard M, Burkhardt B, Rossig C, Kremens B, Lang P, Attarbaschi A, Mann G, Oschlies I, Klapper W, Reiter A: Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)-Type First-Line Therapy: A BFM-Group Study. J Clin Oncol 2011, [Epub ahead of print] [PMID: 21709186]
  3. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A, Berlin-Frankfurt-Münster group: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. Journal of clinical oncology 2010, 28: 3115 [PMID: 20516455]
  4. Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugières L: Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010 1; 28: 3987 [PMID: 20679620]
  5. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British journal of haematology 2010, 149: 578 [PMID: 20331465]
  6. Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, Pulford K, Woessmann W: Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010, 115: 3314 [PMID: 20185586]
  7. Reiter A, Wössmann W: Non-Hodgkin-Lymphome. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Pädiatrische Onkologie und Hämatologie 2009 [URI: http://www.awmf.org/uploads/tx_szleitlinien/025-013.pdf]
  8. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A: Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. Journal of clinical oncology 2009, 27: 3363 [PMID: 19433688]
  9. Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A: Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group. Journal of clinical oncology 2009, 27: 897 [PMID: 19139435]
  10. Landmann E, Oschlies I, Zimmermann M, Moser O, Graf N, Suttorp M, Greiner J, Reiter A, Berlin-Frankfurt-Münster group: Secondary non-Hodgkin lymphoma (NHL) in children and adolescents after childhood cancer other than NHL. British journal of haematology 2008, 143: 387 [PMID: 18729852]
  11. Reiter A, Klapper W: Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. British journal of haematology 2008, 142: 329 [PMID: 18537979]
  12. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006, 24: 491 [PMID: 16421426]
  13. Stanulla M, Seidemann K, Schnakenberg E, Book M, Mehles A, Welte K, Schrappe M, Reiter A: Methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and risk of pediatric non-Hodgkin lymphoma in a German study population. Blood 2005, 105: 906 [PMID: 15632215]
  14. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A, BFM Group: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005, 131: 39 [PMID: 16173961]
  15. Borkhardt A, Wuchter C, Viehmann S, Pils S, Teigler-Schlegel A, Stanulla M, Zimmermann M, Ludwig W, Janka-Schaub G, Schrappe M, Harbott J: Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia 2002, 16: 1685 [PMID: 12200682]
  16. Reiter A, Schrappe M, Ludwig W, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma. Blood 2000, 95: 416 [PMID: 10627444]
  17. Reiter A, Schrappe M, Tiemann M, Ludwig W, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Müller-Weihrich S, Pluss H, Zintl F, Henze G, Riehm H: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy. Blood 1999, 94: 3294 [PMID: 10552938]
  18. Reiter A, Seidemann K, Schrappe M: Therapie der Non-Hodgkin-Lymphome im Kindesalter. Klin Onkologie 1997, 16
  19. Reiter A, Riehm H: Large-cell lymphomas in children. The Non-Hodgkin-Lymphomas 1997, 829
  20. Reiter A: Non-Hodgkin-Lymphome. Diagnostische und therapeutische Standards 1997, 89

Tumours of the central nervous system (CNS-tumours)

Literature on low grade gliomas (LGG)

Search PubMed for recently published articles (external information service)
  1. von Hornstein S, Kortmann RD, Pietsch T, Emser A, Warmuth-Metz M, Soerensen N, Straeter R, Graf N, Thieme B, Gnekow AK: Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: Report from the HIT-LGG 1996 trial. Pediatr Blood Cancer 2011, 1; 56: 1046 [PMID: 21319282]
  2. Rokes CA, Remke M, Guha-Thakurta N, Witt O, Korshunov A, Pfister S, Wolff JE: Sorafenib plus valproic acid for infant spinal glioblastoma. J Pediatr Hematol Oncol 2010, 32: 511 [DOI: 20463608]
  3. Hernáiz Driever P, von Hornstein S, Pietsch T, Kortmann R, Warmuth-Metz M, Emser A, Gnekow AK: Natural history and management of low-grade glioma in NF-1 children. Journal of neuro-oncology 2010, [PMID: 20352473]
  4. Scheiderbauer J, Gnekow AK, Emser A, Hildebrandt G, Bamberg M, Kortmann RD: Multizentrische prospektive kooperative Studie SIOP/GPOH „Low grade glioma„ im Kindesalter von 1996: Ergebnisse nach Strahlentherapie (Deutschland). Strahlenther Onkol 2005, 181 (Sondernr 1): 39
  5. Gnekow AK, Scheiderbauer J, Pietsch T, Soerensen N, Faldum A, Emser A, von Hornstein S, Warmuth-Metz M, Kuehl J: HIT-LGG 1996-Success of a countrywide, comprehensive treatment strategy for children and adolescents with low grade glioma of all histologies and locations. Pedriatric Blood and Cancer 2005, 45: 465
  6. Gnekow AK, Kortmann RD, Pietsch T, Emser A: Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH). Klinische Padiatrie 2004, 216: 331 [PMID: 15565548]
  7. Peters O, Gnekow AK, Rating D, Wolff JE: Impact of location on outcome in children with low-grade oligodendroglioma. Pediatric blood & cancer 2004, 43: 250 [PMID: 15266409]
  8. Peters U, Preisler-Adams S, Lanvers-Kaminsky C, Jürgens H, Lamprecht-Dinnesen A: Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res 2003, 23: 1249

Literature on high grade gliomas (HGG)/glioblastoma multiforme (GBM)

Search PubMed for recently published articles (external information service)
  1. Wolff JE, Mohiuddin K, Jorch N, Graf N, Wagner S, Vats T, Gnekow A: Measuring performance status in pediatric patients with brain tumors--experience of the HIT-GBM-C protocol. Pediatr Blood Cancer 2010, 55: 520 [PMID: 20658624]
  2. Rokes CA, Remke M, Guha-Thakurta N, Witt O, Korshunov A, Pfister S, Wolff JE: Sorafenib plus valproic acid for infant spinal glioblastoma. J Pediatr Hematol Oncol 2010, 32: 511 [DOI: 20463608]
  3. Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, Rutkowski S, Pietsch T, Parker C, Metz MW, Gnekow A, Kramm CM: Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 2010, 116: 705 [PMID: 19957326]
  4. Karremann M, Pietsch T, Janssen G, Kramm CM, Wolff JE: Anaplastic ganglioglioma in children. J Neurooncol 2009, 92: 157 [PMID: 19043777]
  5. Karremann M, Butenhoff S, Rausche U, Pietsch T, Wolff JE, Kramm CM: Pediatric giant cell glioblastoma: New insights into a rare tumor entity. Neuro-oncology 2009, 11: 323 [PMID: 19050301]
  6. Wolff JE, Classen CF, Wagner S, Kortmann RD, Palla SL, Pietsch T, Kühl J, Gnekow A, Kramm CM: Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neurooncol 2008, 87: 155 [PMID: 18209954]
  7. Wolff JE, Berrak S, Koontz Webb SE, Zhang M: Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 2008, 88: 57 [PMID: 18253699]
  8. Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE: Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 2008, 28: 2437 [PMID: 18751431]
  9. Wolff JE, Kramm C, Kortmann RD, Pietsch T, Rutkowski S, Jorch N, Gnekow A, Driever PH: Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008, 90: 309 [PMID: 18679579]
  10. Wagner S, Benesch M, Berthold F, Gnekow AK, Rutkowski S, Sträter R, Warmuth-Metz M, Kortmann RD, Pietsch T, Wolff JE: Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer 95: 991 [PMID: 17047647]
  11. Kramm CM, Wagner S, Van Gool S, Schmid H, Strater R, Gnekow A, Rutkowski S, Wolff JE: Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res 2006, 26: 3773 [PMID: 17094400]

Literature on medulloblastoma, supratentorial PNET, ependymoma

Search PubMed for recently published articles (external information service)
  1. Seifert G, Rutkowski S, Jesse P, Madeleyn R, Reif M, Henze G, Längler A: 2. Anthroposophic Supportive Treatment in Children With Medulloblastoma Receiving First-line Therapy. J Pediatr Hematol Oncol 2011, Epub ahead of print [PMID: 21368673]
  2. von Bueren AO, Warmuth-Metz M, Schlegel PG, Soerensen N, Krauss J, Roggendorf W, Pietsch T, Feiden W, Graf N, Pohl F, Flentje M, Kuehl J, Rutkowski S: Late complete remission of supratentorial primitive neuroectodermal tumor (CNS-PNET) after multiple relapses. Pediatr Blood Cancer 2011, 56: 503 [PMID: 21113945]
  3. Gerber NU, von Hoff K, von Bueren AO, Treulieb W, Warmuth-Metz M, Pietsch T, Soerensen N, Faldum A, Emser A, Schlegel PG, Deinlein F, Kortmann RD, Rutkowski S: Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. J Neurooncol 2011, 102: 459 [PMID: 21308398]
  4. Seifert G, Kanitz JL, Pretzer K, Henze G, Witt K, Reulecke S, Voss A: Improvement of Heart Rate Variability by Eurythmy Therapy After a 6-Week Eurythmy Therapy Training. Integr Cancer Ther 2011, [Epub ahead of print] [PMID: 21733984]
  5. Rutkowski S, Cohen B, Finlay J, Luksch R, Ridola V, Valteau-Couanet D, Hara J, Garre ML, Grill J: Medulloblastoma in young children. Pediatr Blood Cancer 2010, 54: 635 [PMID: 20146217]
  6. Benesch M, Weber-Mzell D, Gerber NU, von Hoff K, Deinlein F, Krauss J, Warmuth-Metz M, Kortmann RD, Pietsch T, Driever PH, Quehenberger F, Urban C, Rutkowski S: Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. J Neurosurg Pediatr 2010, 6: 137 [PMID: 20672934]
  7. Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison DW, Garre ML, Biassoni V, Grundy RG, Finlay JL, Dhall G, Raquin MA, Grill J: Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010, 28: 4961 [PMID: 20940197]
  8. Warmuth-Metz M, Blashofer S, von Bueren AO, von Hoff K, Bison B, Pohl F, Kortmann RD, Pietsch T, Rutkowski S: Recurrence in childhood medulloblastoma. J Neurooncol 2010, Epub ahead of print] [PMID: 21069427]
  9. Massimino M, Giangaspero F, Garrè ML, Gandola L, Poggi G, Biassoni V, Gatta G, Rutkowski S: Childhood medulloblastoma. Crit Rev Oncol Hematol 2010, Epub ahead of print [PMID: 21129995]
  10. Benesch M, Sperl D, von Bueren AO, Schmid I, von Hoff K, Warmuth-Metz M, Ferrari R, Lassay L, Kortmann RD, Pietsch T, Rutkowski S: Primary central nervous system primitive neuroectodermal tumors (CNS-PNETs) of the spinal cord in children: four cases from the German HIT database with a critical review of the literature. J Neurooncol 2010, Epub ahead of print [PMID: 21181235]
  11. von Hoff K, Hartmann W, von Bueren AO, Gerber NU, Grotzer MA, Pietsch T, Rutkowski S: Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatric blood & cancer 2010, 54: 369 [PMID: 19908297]
  12. Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, Wolff JE, Van Gool SW: Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatric blood & cancer 2010, 54: 519 [PMID: 19852061]
  13. Rutkowski S, Gerber NU, von Hoff K, Gnekow A, Bode U, Graf N, Berthold F, Henze G, Wolff JE, Warmuth-Metz M, Soerensen N, Emser A, Ottensmeier H, Deinlein F, Schlegel PG, Kortmann RD, Pietsch T, Kuehl J, German Pediatric Brain Tumor Study Group: Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-oncology 2009, 11: 201 [PMID: 18818397]
  14. Benesch M, Siegler N, Hoff K, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C: Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anti-cancer drugs 2009, 20: 794 [PMID: 19617818]
  15. Rutkowski S, Riehle E: Access to employment and economic independence in cerebral palsy. Physical medicine and rehabilitation clinics of North America 2009, 20: 535 [PMID: 19643352]
  16. von Hoff K, Hinkes B, Gerber NU, Deinlein F, Mittler U, Urban C, Benesch M, Warmuth-Metz M, Soerensen N, Zwiener I, Goette H, Schlegel PG, Pietsch T, Kortmann RD, Kuehl J, Rutkowski S: Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. European journal of cancer (Oxford, England : 1990) 2009, 45: 1209 [PMID: 19250820]
  17. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A: Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. Journal of clinical oncology 2009, 27: 1627 [PMID: 19255330]
  18. von Bueren AO, von Hoff K, Benesch M, Rutkowski S: Dose reductions of vincristine in children with medulloblastoma treated in the maintenance arm of the prospective multicenter trial HIT'91. Klinische Padiatrie 2009, 221: 396 [PMID: 19890797]
  19. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M: Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clinical cancer research 2007, 13: 2651 [PMID: 17473196]
  20. Grotzer MA, von Hoff K, von Bueren AO, Shalaby T, Hartmann W, Warmuth-Metz M, Emser A, Kortmann RD, Kuehl J, Pietsch T, Rutkowski S: Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma. Klinische Padiatrie 2007, 219: 312 [PMID: 18050040]
  21. Rutkowski S: Timely identification of suspected paediatric CNS tumours. The lancet oncology 2007, 8: 664 [PMID: 17679075]
  22. Timmermann B, Kortmann RD, Kühl J, Rutkowski S, Meisner C, Pietsch T, Deinlein F, Urban C, Warmuth-Metz M, Bamberg M: Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. Journal of clinical oncology 2006, 24: 1554 [PMID: 16575007]
  23. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, Graf N, Emser A, Pietsch T, Wolff JE, Kortmann RD, Kuehl J: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. The New England journal of medicine 2005, 352: 978 [PMID: 15758008]
  24. Timmermann B, Kortmann RD, Kühl J, Rutkowski S, Dieckmann K, Meisner C, Bamberg M: Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: results of the prospective German brain tumor trials HIT-SKK 87 and 92. Radiotherapy and oncology 2005, 77: 278 [PMID: 16300848]
  25. Kortmann RD, Timmermann B, Rutkowski S, Bamberg M: Re: B. Beuthien-Baumann, et al. Differentiation between recurrent tumor and radiation necrosis in a child with anaplastic ependymoma after chemotherapy and radiation therapy. Strahlenther Onkol 2003;179:819-22. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 2004, 180: 245 [PMID: 15057436]
  26. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sörensen N, Kühl J: Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998, 16: 2478 [PMID: 9667267]
  27. Scheurlen W, Kühl J: Current diagnostic and therapeutic management of CNS metastasis in childhood primitive neuroectodermal tumors and ependymomas. Journal of neuro-oncology 1998, 38(2-3): 181 [PMID: 9696369]
  28. Scheurlen WG, Seranski P, Mincheva A, Kühl J, Sörensen N, Krauss J, Lichter P, Poustka A, Wilgenbus KK: High-resolution deletion mapping of chromosome arm 17p in childhood primitive neuroectodermal tumors reveals a common chromosomal disruption within the Smith-Magenis region, an unstable region in chromosome band 17p11. 2. Genes, chromosomes & cancer 1997, 18: 50 [PMID: 8993980]

Chorioid-Plexus-Tumoren

Search PubMed for recently published articles (external information service)
  1. Mazloom A, Wolff JE, Paulino AC: The impact of radiotherapy fields in the treatment of patients with choroid plexus carcinoma. Int J Radiat Oncol Biol Phys 2010, 78: 79 [PMID: 20004534]
  2. Subbiah V, Ketonen L, Bruner JM, Nunez R, Weinberg J, Wolff JE: 99mTc-sestamibi scan differentiates tumor from other contrast enhancing tissue in choroid plexus tumors. J Clin Onco 2010, 32: 160 [PMID: 20168252]
  3. Berrak SG, Liu DD, Wrede B, Wolff JE: Which therapy works better in choroid plexus carcinomas? J Neurooncol 2010, Epub ahead of print [PMID: 20976614]
  4. Hasselblatt M, Mühlisch J, Wrede B, Kallinger B, Jeibmann A, Peters O, Kutluk T, Wolff JE, Paulus W, Frühwald MC: Aberrant MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors. J Neurooncol 2009, 91: 151 [PMID: 18795231]
  5. Prasad P, Vasquez H, Das CM, Gopalakrishnan V, Wolff JE: Histone acetylation resulting in resistance to methotrexate in choroid plexus cells. J Neurooncol 2009, 91: 279 [PMID: 18853233]
  6. Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JE: Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol 2009, 95: 383 [PMID: 19543851]
  7. Wrede B, Liu P, Wolff JE: Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. J Neurooncol 2007, 85: 345 [PMID: 17576522]

Germ cell tumours

Intracranial germ cell tumours

Search PubMed for recently published articles (external information service)
  1. Calaminus G: Intrakraniale Keimzelltumoren. Monatsschr Kinderheilkd 2008, 156: 1181–1186 [DOI: 10.1007/s00112-008-1797-5]
  2. Schneider DT, Zahn S, Sievers S, Alemazkour K, Reifenberger G, Wiestler OD, Calaminus G, Göbel U, Perlman EJ: Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2006, 19: 864 [PMID: 16607373]
  3. Göbel U, Calaminus G, Schneider DT, Koch S, Teske C, Harms D: The malignant potential of teratomas in infancy and childhood: the MAKEI experiences in non-testicular teratoma and implications for a new protocol. Klinische Padiatrie 2006, 218: 309 [PMID: 17080332]
  4. Calaminus G, Andreussi L, Garré ML, Kortmann RD, Schober R, Göbel U: Secreting germ cell tumors of the central nervous system (CNS). First results of the cooperative German/Italian pilot study (CNS sGCT). Klinische Padiatrie 1997, 209: 222 [PMID: 9293454]

Extracranial germ cell tumours

Search PubMed for recently published articles (external information service)
  1. Göbel U, Schneider DT, Teske C, Schönberger S, Calaminus G: Brain metastases in children and adolescents with extracranial germ cell tumor - data of the MAHO/MAKEI-registry. Klinische Padiatrie 2010, 222: 140 [PMID: 20514616]
  2. Steffens J, Treiyer A, Calaminus G: [Management of pediatric testicular tumors : diagnosis, therapy, and follow-up]. Der Urologe. Ausg. A 2009, 48: 359 [PMID: 19280171]
  3. Bernbeck B, Schneider DT, Bernbeck B, Koch S, Teske C, Lentrodt J, Harms D, Göbel U, Calaminus G, MAKEI-Study Group: Germ cell tumors of the head and neck: report from the MAKEI Study Group. Pediatric blood & cancer 2009, 52: 223 [PMID: 18937314]
  4. Zahn S, Sievers S, Alemazkour K, Orb S, Harms D, Schulz WA, Calaminus G, Göbel U, Schneider DT: Imbalances of chromosome arm 1p in pediatric and adult germ cell tumors are caused by true allelic loss: a combined comparative genomic hybridization and microsatellite analysis. Genes, chromosomes & cancer 2006, 45: 995 [PMID: 16897744]
  5. Biskup W, Calaminus G, Schneider DT, Leuschner I, Göbel U: Teratoma with malignant transformation: experiences of the cooperative GPOH protocols MAKEI 83/86/89/96. Klinische Padiatrie 2006 Nov-Dec; 218: 303 [PMID: 17080331]
  6. Calaminus G, Bamberg M, Harms D, Jürgens H, Kortmann RD, Sörensen N, Wiestler OD, Göbel U: AFP/beta-HCG secreting CNS germ cell tumors: long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89. Neuropediatrics 2005, 36: 71 [PMID: 15822019]

Neuroblastoma

Literature on neuroblastoma trials

Search PubMed for recently published articles (external information service)
  1. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14. 18 or oral metronomic chemotherapy. BMC Cancer 2011, 18; 11: 21. [PMID: 21244693]
  2. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B: Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011, 56: 578 [PMID: 21298742]
  3. Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H: Dosimetry for (131)I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. European journal of nuclear medicine and molecular imaging 2010, [PMID: 20179922]
  4. Fischer M, Bauer T, Oberthür A, Hero B, Theissen J, Ehrich M, Spitz R, Eils R, Westermann F, Brors B, König R, Berthold F: Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010, 29: 865 [PMID: 19901960]
  5. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force: The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 298 [PMID: 19047290]
  6. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, Niggli F, Schilling F, Schwab M, Simon T, Westermann F, Berthold F, Hero B: Heterogeneity of the MYCN oncogene in neuroblastoma. Clinical cancer research 2009, 15: 2085 [PMID: 19276282]
  7. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 289 [PMID: 19047291]
  8. Benz-Bohm G, Hero B, Gossmann A, Simon T, Körber F, Berthold F: Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma How much diagnostic imaging is necessary? European journal of radiology 2009, [PMID: 19369017]
  9. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M: Molecular characterization and classification of neuroblastoma. Future oncology (London, England) 2009, 5: 625 [PMID: 19519203]
  10. Hoene V, Fischer M, Ivanova A, Wallach T, Berthold F, Dame C: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. British journal of cancer 2009, 101: 1481 [PMID: 19707195]
  11. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clinical chemistry 2009, 55: 1316 [PMID: 19460840]
  12. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma. BMC molecular biology 2009, 10: 28 [PMID: 19348682]
  13. Schrappe M, Creutzig U: Akute lymphoblastische (ALL) und akute myeloische (AML) Leukämie im Kindesalter. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Pädiatrische Onkologie und Hämatologie. AWMF online 2008 [URI: http://www.awmf.org/uploads/tx_szleitlinien/025-014.pdf]
  14. Fischer M, Spitz R, Oberthür A, Westermann F, Berthold F: Risk estimation of neuroblastoma patients using molecular markers. Klinische Padiatrie 2008, 220: 137 [PMID: 18478485]
  15. Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau-Couanet D: MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Molecular oncology 2008, 2: 261 [PMID: 19383347]
  16. Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M: Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14: 6590 [PMID: 18927300]
  17. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F: Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. Journal of clinical oncology 2008, 26: 1504 [PMID: 18349403]
  18. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. Journal of clinical oncology 2008, 26: 5443 [PMID: 18838715]
  19. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, König R, Fischer M, Schwab M: Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome biology 2008, 9:R150 [PMID: 18851746]
  20. Simon T, Längler A, Berthold F, Klingebiel T, Hero B: Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2007, 29: 101 [PMID: 17279006]
  21. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Molecular cancer research : MCR 2007, 5: 1276 [PMID: 18171985]
  22. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H: Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin. Nuclear medicine 2006, 45: 145-51; quiz N39 [PMID: 16964339]
  23. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F: Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes, chromosomes & cancer 2006, 45: 1130 [PMID: 16958102]
  24. Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, Fischer M: Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer letters 2007, 250: 250 [PMID: 17126996]
  25. Spitz R, Hero B, Simon T, Berthold F: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clinical cancer research 2006, 12(11 Pt 1): 3368 [PMID: 16740759]
  26. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24: 5070 [PMID: 17075126]
  27. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F: Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clinical cancer research : an official journal of the American Association for Cancer Research 2006, 12: 5118 [PMID: 16951229]
  28. Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F: Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlentherapie und Onkologie 2006, 182: 389 [PMID: 16826357]
  29. Schumacher-Kuckelkorn R, Hero B, Ernestus K, Berthold F: Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases. Pediatric blood & cancer 2005, 45: 195 [PMID: 15800908]
  30. Fischer M, Skowron M, Berthold F: Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. The Journal of molecular diagnostics 2005, 7: 89 [PMID: 15681479]
  31. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F: Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer immunology, immunotherapy : CII 2005, 54: 400 [PMID: 15449039]
  32. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. The lancet oncology 2005, 6: 649 [PMID: 16129365]
  33. Eich HT, Muller RP, Micke O, Kocher M, Berthold F, Hero B: Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlentherapie und Onkologie 2005, 181: 378 [PMID: 15925980]
  34. Boensch M, Oberthuer A, Fischer M, Skowron M, Oestreich J, Berthold F, Spitz R: Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q. Diagnostic molecular pathology 2005, 14: 177 [PMID: 16106200]
  35. Simon A, Beutel K, Marklein G, Fleischhack G: Bacterial infections in pediatric cancer patients. Klin Pädiatr 2005, 217 Suppl 1:S17 [PMID: 16288351]
  36. Hero B, Berthold F: Neuroblastoma. In: D. Reinhard (Hrsg.), Leitlinien Kinderheilkunde und Jugendmedizin Urban & Fischer, 2005, L5 1 [ISBN: 3-437-21867-0
  37. Berthold F, Simon T: Clinical Presentation. In: Cheung NK, Cohn SL (Hrsg.). Neuroblastoma Springer Verlag. 2005, 63 [ISBN: 3-540-40841-X
  38. Claviez A, Lakomek M, Ritter J, Suttorp M, Kremens B, Dickerhoff R, Harms D, Berthold F, Hero B: Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies. European journal of cancer (Oxford, England : 1990) 2004, 40: 2760 [PMID: 15648116]
  39. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F: Consolidation treatment with chimeric anti-GD2-antibody ch14. 18 in children older than 1 year with metastatic neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004, 22: 3549 [PMID: 15337804]
  40. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer research 2004, 64: 6883 [PMID: 15466177]
  41. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F: MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. European journal of cancer (Oxford, England : 1990) 2004, 40: 2753 [PMID: 15571958]
  42. Jensen M, Tawadros S, Sedlacek HH, Schultze JL, Berthold F: NK cell depletion diminish tumour-specific B cell responses. Immunology letters 2004, 93(2-3): 205 [PMID: 15158618]
  43. Schilling FH, Spix C, Berthold F, Erttmann R, Sander J, Treuner J, Michaelis J: Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer letters 2003, 197(1-2): 19 [PMID: 12880955]
  44. Spitz R, Hero B, Ernestus K, Berthold F: Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2003, 9: 4835 [PMID: 14581355]
  45. Krams M, Heidebrecht HJ, Hero B, Berthold F, Harms D, Parwaresch R, Rudolph P: Repp86 expression and outcome in patients with neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003, 21: 1810 [PMID: 12721258]
  46. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C: Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer letters 2003, 197(1-2): 11 [PMID: 12880954]
  47. Simon T, Hero B, Hunneman DH, Berthold F: Tumour markers are poor predictors for relapse or progression in neuroblastoma. European journal of cancer (Oxford, England : 1990) 2003, 39: 1899 [PMID: 12932669]
  48. Jensen M, Ernestus K, Kemshead J, Klehr M, Von Bergwelt-Baildon MS, Schinkothe T, Schultze JL, Berthold F: The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. Clinical and experimental immunology 2003, 134: 253 [PMID: 14616785]

Osteosarcoma

Literature on osteosarcoma trials

Search PubMed for recently published articles (external information service)
  1. Bielack S, Jürgens H, Jundt G, Kevric M, Kühne T, Reichardt P, Zoubek A, Werner M, Winkelmann W, Kotz R: Osteosarcoma: The COSS Experience. Cancer treatment and research 2010, 152: 289 [PMID: 20213397]
  2. Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S: The role of radiotherapy in oseosarcoma. Cancer treatment and research 2010, 152: 147 [PMID: 20213389]
  3. Kager L, Pötschger U, Bielack S: Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag 2010, 24; 6: 279 [PMID: 20596505]
  4. Kager L, Kempf-Bielack B, Bielack S: Synchronous and metachronous lung metastases in high-grade osteosarcoma. Japanese journal of clinical oncology 2010, 40: 94 [PMID: 19914945]
  5. Bielack SS: Osteosarcoma: time to move on? European journal of cancer 2010, 46: 1942 [PMID: 20385483]
  6. Franke M, Hardes J, Helmke K, Jundt G, Jürgens H, Kempf-Bielack B, Kevric M, Tunn PU, Werner M, Bielack S: Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer 2011, 56: 771 [PMID: 21162070]
  7. Kager L, Zoubek A, Dominkus M, Lang S, Bodmer N, Jundt G, Klingebiel T, Jürgens H, Gadner H, Bielack S, for the COSS Study Group: Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group. Cancer 2010, [PMID: 20672353]
  8. Bielack SS, Franke M: Re: Late recurrence in pediatric cancer: a report from the childhood cancer survivor study. Journal of the National Cancer Institute 2010, 102: 828; author reply 828 [PMID: 20424235]
  9. Bielack SS, Carrle D, Hardes J, Schuck A, Paulussen M: Bone tumors in adolescents and young adults. Current treatment options in oncology 2008, 9: 67 [PMID: 18449804]
  10. Bielack S: Pediatric extraskeletal osteosarcoma. Pediatric radiology 2008, 38: 1033 [PMID: 18521586]
  11. Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS, Reaman GH: Osteosarcoma: the same old drugs or more? Journal of clinical oncology 2008, 26: 3102-3; author reply 3104 [PMID: 18565904]
  12. Bielack SS, Carrle D: State-of-the-art approach in selective curable tumors: bone sarcoma. Annals of oncology 2008, 19 Suppl 7:vii155 [PMID: 18790938]
  13. Bielack S: Osteosarkome. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Gesellschaft für Pädiatrische Onkologie und Hämatologie AWMF online, 2008 [URI: http://www.uni-duesseldorf.de/AWMF/ll/025-005.htm]
  14. Kersting C, Gebert C, Agelopoulos K, Schmidt H, van Diest PJ, Jürgens H, Winkelmann W, Kevric M, Gosheger G, Brandt B, Bielack S, Buerger H: Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clinical cancer research 2007, 13: 2998 [PMID: 17505002]
  15. Paulides M, Dörr HG, Stöhr W, Bielack S, Koscielniak E, Klingebiel T, Jürgens H, Bölling T, Willich N, Sauer R, Langer T, Beck JD, Late Effects Surveillance System: Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System. Clinical endocrinology 2007, 66: 727 [PMID: 17381483]
  16. Potratz J, Zoubek A, Bielack, S: Malignant bone tumors in children and adolescents. Monatsschr Kinderheilkd 2006, 154; 10
  17. Paulides M, Kremers A, Stohr W, Bielack S, Jürgens H, Treuner J, Beck JD, Langer T, German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH): Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatric blood & cancer 2006, 46: 489 [PMID: 16333817]
  18. Grimer RJ, Bielack S, Flege S, Cannon SR, Foleras G, Andreeff I, Sokolov T, Taminiau A, Dominkus M, San-Julian M, Kollender Y, Gosheger G, European Musculo Skeletal Oncology Society: Periosteal osteosarcoma--a European review of outcome. European journal of cancer (Oxford, England : 1990) 2005, 41: 2806 [PMID: 16290134]
  19. Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). Journal of clinical oncology 2005, 23: 559 [PMID: 15659502]
  20. Goldstein-Jackson SY, Gosheger G, Delling G, Berdel WE, Exner GU, Jundt G, Machatschek JN, Zoubek A, Jürgens H, Bielack SS, Cooperative Osteosarcoma Study Group COSS: Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. Journal of cancer research and clinical oncology 2005, 131: 520 [PMID: 15918046]
  21. Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H, Jürgens H, Mayer-Steinacker R, Gosheger G, Bielack SS: Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatric blood & cancer 2005, [PMID: 16206218]
  22. Daecke W, Bielack S, Martini AK, Ewerbeck V, Jürgens H, Kotz R, Winkelmann W, Kabisch H, Kevric M, Bernd L: Osteosarcoma of the hand and forearm: experience of the Cooperative Osteosarcoma Study Group. Annals of surgical oncology : the official journal of the Society of Surgical Oncology 2005, 12: 322 [PMID: 15827675]
  23. Stohr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD, German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology: Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer investigation 2005, 23: 201 [PMID: 15945505]
  24. Kreuter M, Bieker R, Bielack SS, Auras T, Buerger H, Gosheger G, Jürgens H, Berdel WE, Mesters RM: Prognostic relevance of increased angiogenesis in osteosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2004, 10: 8531 [PMID: 15623635]
  25. Leidinger B, Bielack S, Koehler G, Vieth V, Winkelmann W, Gosheger G: High level of beta-hCG simulating pregnancy in recurrent osteosarcoma: case report and review of literature. Journal of cancer research and clinical oncology 2004, 130: 357 [PMID: 15042358]

Ewing-Sarcoma

Literature on Ewing-Sarcoma trials

Search PubMed for recently published articles (external information service)
  1. Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, Yoshimi A, Peters C, Ladenstein R, Pession A, Prete A, Urban EC, Schwinger W, Bordigoni P, Salmon A, Diaz MA, Afanasyev B, Lisukov I, Morozova E, Toren A, Bielorai B, Korsakas J, Fagioli F, Caselli D, Ehninger G, Gruhn B, Dirksen U, Abdel-Rahman F, Aglietta M, Mastrodicasa E, Torrent M, Corradini P, Demeocq F, Dini G, Dreger P, Eyrich M, Gozdzik J, Guilhot F, Holler E, Koscielniak E, Messina C, Nachbaur D, Sabbatini R, Oldani E, Ottinger H, Ozsahin H, Schots R, Siena S, Stein J, Sufliarska S, Unal A, Ussowicz M, Schneider P, Woessmann W, Jürgens H, Bregni M, Burdach S, on behalf of the Solid Tumor Working Party (STWP) and the Pediatric Disease Working Party (PDWP) of the European Group for Blood and Marrow Transplantation (EBMT), the Asia Pacific Blood and Marrow Transplantation (APBMT), the Pediatric Registry for Stem: No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 2011, 22: 1614 [PMID: 21245159]
  2. Dirksen U, Jürgens H: Approaching Ewing sarcoma. Future Oncol 2010, 6: 1155 [PMID: 20624127]
  3. Burdach S, Thiel U, Schöniger M, Haase R, Wawer A, Nathrath M, Kabisch H, Urban C, Laws HJ, Dirksen U, Steinborn M, Dunst J, Jürgens H, Meta-EICESS Study Group: Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases. Bone marrow transplantation 2010, 45: 483 [PMID: 19684633]
  4. Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jürgens H: Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. Journal of clinical oncology 2010, 28: 3284 [PMID: 20547982]
  5. Paulussen M, Bielack S, Jürgens H, Casali PG, ESMO Guidelines Working Group: Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of oncology 2009, 20 Suppl 4: 140 [PMID: 19454436]
  6. Bölling T, Dirksen U, Ranft A, Ernst I, Jürgens H, Willich N: Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data. Strahlenther Onkol 2009, 185 Suppl 2: 21 [PMID: 19685030]
  7. Bölling T, Schuck A, Paulussen M, Dirksen U, Ranft A, Könemann S, Dunst J, Willich N, Jürgens H: Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial. Strahlentherapie und Onkologie 2008, 184: 193 [PMID: 18398583]
  8. Pieper S, Ranft A, Braun-Munzinger G, Jürgens H, Paulussen M, Dirksen U: Ewing's tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E. W.I. N.G. 99. Onkologie 2008, 31: 657 [PMID: 19060503]
  9. Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H, European Intergroup Cooperative Ewing's Sarcoma Study-92: Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. Journal of clinical oncology 2008, 26: 4385 [PMID: 18802150]
  10. Lanvers-Kaminsky C, Bremer A, Dirksen U, Jürgens H, Boos J: Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anti-cancer drugs 2006, 17: 657 [PMID: 16917211]
  11. Ladenstein R, Whelan J, Oberlin O, Weston C, Juergens, H: A prospective multicentre evaluation of intensive treatment including high-dose chemotherapy and PSCR for Ewing's tumours with extra-pulmonary metastatic disease. Results from the Euro-Ewing 99 Study. Bone Marrow Transplant 2006, 37 Suppl.; 16
  12. Lanvers-Kaminsky C, Nolting DM, Koster J, Schroder A, Sandkotter J, Boos J: In-vitro toxicity of Ukrain against human Ewing tumor cell lines. Anti-cancer drugs 2006, 17: 1025 [PMID: 17001175]
  13. Paulides M, Stohr W, Bielack S, Jürgens H, Koscielniak E, Klingebiel T, Zimmermann R, Stachel D, Langer T, Beck JD: Prospective evaluation of hepatitis B, C and HIV infections as possible sequelae of antineoplastic treatment in paediatric sarcoma patients: a report from the Late Effects Surveillance System. Oncology reports 2006, 15: 687 [PMID: 16465431]
  14. Ladenstein R, Poetschger U, Hartman O, Jürgens H, Koscielniak E, Dallorso G, Doz F, Dini, G: Megatherapy/SCT activity in paediatric solid tumours in Europe. Bone Marrow Transplant 2006, 37 Suppl.; 149
  15. Franzius C, Juergens KU, Vormoor J: PET/CT with diagnostic CT in the evaluation of childhood sarcoma. AJR. American journal of roentgenology 2006, 186: 581; author reply 581 [PMID: 16423975]
  16. Bernstein M, Kovar H, Paulussen M, Randall, RL, Schuck A, Teot, LA, Juergens, H: Ewing Sarcoma Family of Tumors: Ewing Sarcoma of Bone and Soft Tissue and the Peripheral Primitive Neuroectodermal Tumors. Buch: Principles and Practice of Pediatric Oncology (Ed. Pizzo,P.A.; Poplack,D.G.) 2006, 5th Ed.;Ch.33; 1002
  17. Potratz J, Zoubek A, Bielack, S: Malignant bone tumors in children and adolescents. Monatsschr Kinderheilkd 2006, 154; 10
  18. Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C, Kessler T, Jürgens H, Berdel WE, Mesters RM: Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma. European journal of cancer (Oxford, England : 1990) 2006, 42: 1904 [PMID: 16824746]
  19. Franzius C, Hotfilder M, Poremba C, Hermann S, Schafers K, Gabbert HE, Jürgens H, Schober O, Schafers M, Vormoor J: Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model. European journal of nuclear medicine and molecular imaging 2006, 33: 1432 [PMID: 16896672]
  20. Gebert C, Brinkschmidt C, Bielack S, Bernhardt T, Jürgens H, Böcker W, Winkelmann W, Bürger H, Gosheger, G: The potential of comparative genomic hybridization as a tool in the differential diagnosis of matrix-producing bone lesions. Int J Surg Pathol 2006, 14: 187 [PMID: 16959697]
  21. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Jürgens H: Ewing's sarcoma family of tumors: current management. The oncologist 2006, 11: 503 [PMID: 16720851]
  22. Paulides M, Kremers A, Stohr W, Bielack S, Jürgens H, Treuner J, Beck JD, Langer T, German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH): Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatric blood & cancer 2006, 46: 489 [PMID: 16333817]
  23. Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H: Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatric blood & cancer 2006, 47: 795 [PMID: 16411206]
  24. Borowski A, Dirksen U, Lixin L, Shi, RL, G÷bel U, Schneider, EM: Structure and function of ETAA16: a novel cell surface antigen in Ewing's tumours. Cancer Immunol Immunother Vol.55; 2006, 363 [PMID: 16003559]
  25. Hoffmann C, Gosheger G, Gebert C, Jürgens H, Winkelmann, N: Functional results and quality of life after treatment of pelvic sarcomas involving the acetabulum. J Bone Joint Surg Am 88A; 3/2006, 575
  26. Whelan J, McTiernan A, Weston C, Douglas C, Grimer R, Cassoni A, Paulussen M, Jürgens H, Craft A, Lewis, I: Consequences of different approaches to local treatment of Ewing's sarcoma within an international randomised controlled trial: Analysis of EICESS-92. Journal of Clinical Oncology 2006, 24; 528S
  27. Schuck A, Ranft A, Dirksen U, Dunst J, Jürgens H, Willich, N: Radiotherapy in Ewing tumours: Significance of fractionation. Strahlentherapie und Onkologie 2006, 182; 67
  28. Schuck A, Hamelmann V, Bramswig JH, Konemann S, Rube C, Hesselmann S, Riesenbeck D, Horst E, Bolling T, Paulussen M, Jürgens H, Willich N: Ovarian function following pelvic irradiation in prepubertal and pubertal girls and young adult women. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2005, 181: 534 [PMID: 16044222]
  29. Schuck A, Ahrens S, von Schorlemer I, Kuhlen M, Paulussen M, Hunold A, Gosheger G, Winkelmann W, Dunst J, Willich N, Jürgens H: Radiotherapy in Ewing tumors of the vertebrae: treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials. International journal of radiation oncology, biology, physics 2005, 63: 1562 [PMID: 16137838]
  30. Lanvers-Kaminsky C, Winter B, Koling S, Frodermann B, Braun Y, Schaefer KL, Diallo R, Koenemann S, Wai D, Willich N, Poremba C, Schuck A: Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo. Oncology reports 2005, 14: 751 [PMID: 16077987]
  31. Paulussen M, Jürgens H, Dunst J, Schmoll, HJ, Winkelmann W, Hoffmann, C: Ewing-Tumor (Ewing-Sarkom und maligner peripherer neuroektodermaler Tumor, PNET). Book Chapter In "Kompendium Internistische Onkologie, Standards in Diagnostik und Therapie - Teil 2: Therapiekonzepte maligner Tumoren" (Ed. Schmoll,H.J.; Höffken,K.; Possinger,K.) 2005, 4th Ed.; 5292
  32. Daecke W, Ahrens S, Jürgens H, Martini AK, Ewerbeck V, Kotz R, Winkelmann W, Bernd L: Ewing's sarcoma and primitive neuroectodermal tumor of hand and forearm. Experience of the Cooperative Ewing's Sarcoma Study Group. Journal of cancer research and clinical oncology 2005, 131: 219 [PMID: 15614525]
  33. Paulussen M, Kovar H, Jürgens H: Ewing sarcoma and peripheral PNET. Buchbeitrag 2005, 5. Aufl.
  34. Hotfilder M, Sondermann P, Senss A, van Valen F, Jürgens H, Vormoor J: PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. British journal of cancer 2005, 92: 705 [PMID: 15685229]
  35. Konemann S, Bolling T, Kolkmeyer A, Riesenbeck D, Hesselmann S, Vormoor J, Willich N, Schuck A: Heterogeneity of radiation induced apoptosis in Ewing Tumor cell lines characterized on a single cell level. Apoptosis 2005, 10: 177 [PMID: 15711933]
  36. Gerth HU, Rompel A, Krebs B, Boos J, Lanvers-Kaminsky C: Cytotoxic effects of novel polyoxotungstates and a platinum compound on human cancer cell lines. Anti-cancer drugs 2005, 16: 101 [PMID: 15613912]
  37. Masjosthusmann K, Bielack SS, Kohler G, Florax A, Schiborr M, Bruch J, Reinhardt D, Kuhn N, Paulussen M, Jürgens H: Concomitant Ewing sarcoma and acute lymphoblastic leukemia in a 5-year-old girl. Pediatric blood & cancer 2005, 45: 846 [PMID: 15926159]
  38. Machatschek JN, Paulussen M, Bielack S: Chemotherapie bei malignen Knochentumoren. Buchbeitrag 2005
  39. Paulides M, Stöhr W, Bielack S, Jürgens H, Treuner J, Schuck A, Willich N, Sauer R, Dörr, HG, Rascher W, Langer T, Beck, JD: Major sequelae of antineoplastic therapy prospectively evaluated in 162 relapse-free adult sarcoma patients. Onkologie 2005, 28;S3; 56
  40. Schuck A, Kuhlen M, von Schorlemer L, Ahrens S, Hunold A, Konemann S, Dunst J, Winkelmann W, Jürgens H, Willich N : Radiotherapy in Ewing's tumors of the vertebral column - Results and analysis of local recurrences. STRAHLENTHERAPIE UND ONKOLOGIE 180: 24-24 Suppl. 1, JUN 2004 [ISSN: 0179-7158]
  41. Paulussen M, Jürgens H: Ewing-Sarkom und PNET. Buchbeitrag 2004

Soft tissue sarcomas

Literature on soft tissue sarcoma trials

Search PubMed for recently published articles (external information service)
  1. Seitz G, Dantonello TM, Int-Veen C, Blumenstock G, Godzinski J, Klingebiel T, Schuck A, Leuschner I, Koscielniak E, Fuchs J, on behalf of the CWS-96 Study Group: Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS-96. Pediatr Blood Cancer 2011, 56: 718 [PMID: 21370402]
  2. Stegmaier S, Poremba C, Schaefer KL, Leuschner I, Kazanowska B, Békássy AN, Bielack SS, Klingebiel T, Koscielniak E: Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer 2011, 57: 406 [PMID: 21254373]
  3. Siepermann M, Koscielniak E, Dantonello T, Klee D, Boos J, Krefeld B, Borkhardt A, Hoehn T, Asea A, Wessalowski R: Oral low-dose chemotherapy: Successful treatment of an alveolar rhabdomyosarcoma during pregnancy. Pediatr Blood Cancer 2011, [Epub ahead of print] [PMID: 21241005]
  4. Dantonello TM, Winkler P, Boelling T, Friedel G, Schmid I, Mattke AC, Ljungman G, Bielack SS, Klingebiel T, Koscielniak E, CWS Study Group: Embryonal rhabdomyosarcoma with metastases confined to the lungs: report from the CWS Study Group. Pediatr Blood Cancer 2011, 56: 725 [PMID: 21370403]
  5. Bien E, Kazanowska B, Dantonello T, Adamkiewicz-Drozynska E, Balcerska A, Madziara W, Rybczynska A, Nurzynska-Flak J, Solarz E, Kurylak A, Zalewska-Szewczyk B, Krawczyk M, Izycka-Swieszewska E, Rapala M, Koscielniak E: Factors predicting survival in childhood malignant and intermediate vascular tumors : retrospective analysis of the Polish and German cooperative paediatric soft tissue sarcoma study groups and review of the literature. Ann Surg Oncol 2010, 17: 1878 [PMID: 20333551]
  6. Kuçi S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, Willasch A, Kuçi Z, Koscielniak E, Klöss S, von Laer D, Klingebiel T, Bader P: Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 95: 1579 [PMID: 20378565]
  7. Dantonello TM, Winkler P, Boelling T, Friedel G, Schmid I, Mattke AC, Ljungman G, Bielack SS, Klingebiel T, Koscielniak E, on behalf of the CWS Study Group: Embryonal rhabdomyosarcoma with metastases confined to the lungs: Report from the CWS Study Group. Pediatr Blood Cancer 2010, [Epub ahead of print] [PMID: 21061312]
  8. Mattke AC, Bailey EJ, Schuck A, Dantonello T, Leuschner I, Klingebiel T, Treuner J, Koscielniak E: Does the time-point of relapse influence outcome in pediatric rhabdomyosarcomas? Pediatric blood & cancer 2009, 52: 772 [PMID: 19165889]
  9. Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, Jürgens H, Scheel-Walter HG, Bielack SS, Klingebiel T, Dickerhoff R, Kirsch S, Brecht I, Schmelzle R, Greulich M, Gadner H, Greiner J, Marky I, Treuner J, Koscielniak E: Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. Journal of clinical oncology 2009, 27: 1446 [PMID: 19224858]
  10. Dantonello TM, Int-Veen C, Winkler P, Leuschner I, Schuck A, Schmidt BF, Lochbuehler H, Kirsch S, Hallmen E, Veit-Friedrich I, Bielack SS, Niggli F, Kazanowska B, Ladenstein R, Wiebe T, Klingebiel T, Treuner J, Koscielniak E: Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. Journal of clinical oncology 2008, 26: 406 [PMID: 18202417]
  11. Weihkopf T, Blettner M, Dantonello T, Jung I, Klingebiel T, Koscielniak E, Lückel M, Spix C, Kaatsch P: Incidence and time trends of soft tissue sarcomas in German children 1985-2004 - a report from the population-based German Childhood Cancer Registry. European journal of cancer 2008, 44: 432 [PMID: 18077150]
  12. Reiter A, Klapper W: Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. British journal of haematology 2008, 142: 329 [PMID: 18537979]
  13. Klingebiel T, Boos J, Beske F, Hallmen E, Int-Veen C, Dantonello T, Treuner J, Gadner H, Marky I, Kazanowska B, Koscielniak E: Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatric blood & cancer 2008, 50: 739 [PMID: 18286501]
  14. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U, Lanvers-Kaminsky C, Jürgens H, Herrero D, Stegmaier S, Koscielniak E, Eggert A, Nathrath M, Gosheger G, Schneider DT, Bury C, Diallo-Danebrock R, Ottaviano L, Gabbert HE, Poremba C: Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. European journal of cancer (Oxford, England : 1990) 2008, 44: 699 [PMID: 18294840]
  15. Dantonello TM, Int-Veen C, Leuschner I, Schuck A, Furtwaengler R, Claviez A, Schneider DT, Klingebiel T, Bielack SS, Koscielniak E: Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults : experiences of the CWS and COSS study groups. Cancer 2008, 112: 2424 [PMID: 18438777]
  16. Koscielniak E, Treuner J: Weichteilsarkome. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und Leitlinien und der Gesellschaft für Pädiatrische Onkologie und Hämatologie 2008 [URI: http://www.uni-duesseldorf.de/AWMF/ll/025-007.htm]
  17. Stöhr W, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, Langer T, Beck JD: Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatric blood & cancer 2007, 48: 140 [PMID: 16724313]
  18. Kazanowska B, Reich A, Stegmaier S, Békássy AN, Leuschner I, Chybicka A, Koscielniak E: Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Fetal and pediatric pathology 2007, 26: 17 [PMID: 17613043]
  19. Paulides M, Dörr HG, Stöhr W, Bielack S, Koscielniak E, Klingebiel T, Jürgens H, Bölling T, Willich N, Sauer R, Langer T, Beck JD, Late Effects Surveillance System: Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System. Clinical endocrinology 2007, 66: 727 [PMID: 17381483]
  20. Gieseke F, Schütt B, Viebahn S, Koscielniak E, Friedrich W, Handgretinger R, Müller I: Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood 2007, 110: 2197 [PMID: 17522338]
  21. Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, Langer T, Beck JD: Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatric blood & cancer 2007, 48: 447 [PMID: 16628552]
  22. Hanke CA, Roessler J, Stegmaier S, Koscielniak E, Niemeyer CM, Kontny U: Alveolar rhabdomyosarcoma mimicking lymphoma with bone marrow involvement. European journal of pediatrics 2007, 166: 505 [PMID: 17008999]
  23. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schäfer BW: Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. Journal of clinical oncology 2006, 24: 816 [PMID: 16391296]

Rhabdoid tumours

Literature on Rhabdoid Tumours

Search PubMed for recently published articles (external information service)
  1. Schneppenheim R, Frühwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, Kreuz M, Leuschner I, Martin Subero JI, Obser T, Oyen F, Vater I, Siebert R: Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. American journal of human genetics 2010, 86: 279 [PMID: 20137775]
  2. van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, Coulombe A, Patte C, de Camargo B, de Kraker J, Leuschner I, Lugtenberg R, Pritchard-Jones K, Sandstedt B, Spreafico F, Graf N, Vujanic GM: Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group. Pediatr Blood Cancer 2010 [Epub ahead of print] [PMID: 21182029]
  3. Lünenbürger H, Lanvers-Kaminsky C, Lechtape B, Frühwald MC: Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. Anti-cancer drugs 2010, 21: 514 [PMID: 20147838]
  4. Frühwald MC, Krefeld B, Benesch M, Büchner J, Boos J, Ebetsberger G, Graf N, Kortmann R, Nysom K, Rutkowski S, Schneppenheim R, Siebert R, Timmermann B, Warmuth-Matz M, Hasselblatt M: The European Rhabdoid Registry (EU-RHAB) – A comprehensive approach towards biology and clinical management. Neurooncology 2010, 12:ii36 [DOI: 10.1093/neuonc/noq043]
  5. Reinhard H, Reinert J, Beier R, Furtwängler R, Alkasser M, Rutkowski S, Frühwald M, Koscielniak E, Leuschner I, Kaatsch P, Graf N: Rhabdoid tumors in children: prognostic factors in 70 patients diagnosed in Germany. Oncology reports 2008, 19: 819 [PMID: 18288421]

Nephroblastoma (Wilms Tumour)

Literature on Wilms Tumour trials

Search PubMed for recently published articles (external information service)
  1. Furtwängler R, Nourkami N, Alkassar M, von Schweinitz D, Schenk JP, Rübe C, Siemer S, Leuschner I, Graf N: Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies - a report from the GPOH-nephroblastoma study group. Klin padiatr 2011, 223: 113 [PMID: 21509706]
  2. Schenk JP, Gunther P, Schrader C, Ley S, Furtwangler R, Leuschner I, Edelhauser M, Graf N, Troger J: [Childhood kidney tumors - the relevance of imaging.] Der Radiologe 2005, 45: 1112 [PMID: 16151729]
  3. Schenk JP, Schrader C, Furtwangler R, Ko HS, Leuschner I, Graf N, Troeger J: [MRI-morphology and staging of congenital mesoblastic nephroma: evaluation of a collection with 20 patients]. RoFo 2005, 177: 1373 [PMID: 16170706]
  4. Schlomm T, Gunawan B, Schulten HJ, Sander B, Thangavelu K, Graf N, Leuschner I, Ringert RH, Fuzesi L: Effects of chemotherapy on the cytogenetic constitution of Wilms' tumor. Clinical cancer research 2005, 11: 4382 [PMID: 15958621]
  5. Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, Graf N, Eilers M, Gessler M: Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. International journal of cancer 2006, 118: 1954 [PMID: 16287080]
  6. Schenk JP, Engelmann D, Zieger B, Semler O, Wuhl E, Furtwangler R, Graf N, Troger J: [Radiologic differentiation of rhabdoid tumor from Wilms' tumor and mesoblastic nephroma]. Der Urologe. Ausg. A 2005, 44: 155 [PMID: 15672236]
  7. Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N, Gessler M: Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes, chromosomes & cancer 2006, 45: 565 [PMID: 16575872]
  8. Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M: All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 2005, 24: 5246 [PMID: 15897880]
  9. Zirn B, Wittmann S, Graf N, Gessler M: Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development. Cancer letters 2005, 220: 115 [PMID: 15737694]
  10. Schenk JP, Waag KL, Graf N, Wunsch R, Jourdan C, Behnisch W, Troger J, Gunther P: [3D-visualization by MRI for surgical planning of Wilms tumors]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2004, 176: 1447 [PMID: 15383976]
  11. Reinhard H, Aliani S, Ruebe C, Stockle M, Leuschner I, Graf N: Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004, 22: 4500 [PMID: 15542800]
  12. Siemer S, Lehmann J, Reinhard H, Graf N, Loffler G, Hendrik H, Remberger K, Stockle M: Prenatal diagnosis of congenital mesoblastic nephroma associated with renal hypertension in a premature child. International journal of urology : official journal of the Japanese Urological Association 2004, 11: 50 [PMID: 14678186]
  13. de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF, SIOP: Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 2004, 364: 1229 [PMID: 15464183]
  14. van den Heuvel-Eibrink MM, Graf N, Pein F, Sandstedt B, van Tinteren H, van der Vaart KE, de Kraker J: Intracranial relapse in Wilms tumor patients. Pediatric blood & cancer 2004, 43: 737 [PMID: 15390287]

Hepatoblastoma

Literature on hepatoblastoma /-carcinoma trials

Search PubMed for recently published articles (external information service)
  1. Grotegut S, Kappler R, Tarimoradi S, Lehembre F, Christofori G, Von Schweinitz D: Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation. International journal of oncology 2010, 36: 1261 [PMID: 20372801]
  2. Eichenmüller M, Gruner I, Hagl B, Häberle B, Müller-Höcker J, von Schweinitz D, Kappler R: Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009, 49: 482 [PMID: 19177589]
  3. Hartmann W, Küchler J, Koch A, Friedrichs N, Waha A, Endl E, Czerwitzki J, Metzger D, Steiner S, Wurst P, Leuschner I, von Schweinitz D, Buettner R, Pietsch T: Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clinical cancer research 2009, 15: 4538 [PMID: 19584164]
  4. Eichenmüller M, von Schweinitz D, Kappler R: Betulinic acid treatment promotes apoptosis in hepatoblastoma cells. International journal of oncology 2009, 35: 873 [PMID: 19724925]
  5. Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G: Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. Journal of clinical oncology 2010, 28: 2584 [PMID: 20406943]
  6. Koch A, Waha A, Hartmann W, Hrychyk A, Schuller U, Waha A, Wharton KA Jr, Fuchs SY, von Schweinitz D, Pietsch T: Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clinical cancer research 2005, 11: 4295 [PMID: 15958610]
  7. Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, Maibach R, Perilongo G, Shafford E, Plaschkes J, International Society of Pediatric Oncology (SIOP): Otte JB, Pritchard J, Aronson DC, et al.: Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004, 42: 74-83. [PMID: 14752798]
  8. Koch A, Weber N, Waha A, Hartmann W, Denkhaus D, Behrens J, Birchmeier W, von Schweinitz D, Pietsch T: Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. The Journal of pathology 2004, 204: 546 [PMID: 15538750]
  9. Albrecht S, Hartmann W, Houshdaran F, Koch A, Gartner B, Prawitt D, Zabel BU, Russo P, Von Schweinitz D, Pietsch T: Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15. 5 in hepatoblastoma. International journal of cancer. Journal international du cancer 2004, 111: 627 [PMID: 15239143]

Rare tumours and rare diseases

Network for Rare Tumours

  1. Schneider DT, Brecht IB: Care for rare cancers: improved care requires improved communication. Klinische Padiatrie 2010, 222: 124 [PMID: 20514613]
  2. Brecht IB, Graf N, Schweinitz D, Frühwald MC, Bielack SS, Schneider DT: Networking for children and adolescents with very rare tumors: foundation of the GPOH Pediatric Rare Tumor Group. Klinische Padiatrie 2009, 221: 181 [PMID: 19437371]
  3. Ferrari A, Bisogno G, De Salvo GL, Indolfi P, Perilongo G, Cecchetto G, Italian Study on Rare Tumours in Paediatric Age (TREP),Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP): The challenge of very rare tumours in childhood: the Italian TREP project. European journal of cancer 2007, 43: 654 [PMID: 17049226]

Literature on malignant endocrine tumours (MEN)

Search PubMed for recently published articles (external information service)
  1. Oommen PT, Romahn A, Linden T, Frühwald MC, Bucsky P: UICC-2002 TNM classification is not suitable for differentiated thyroid cancer in children and adolescents. Pediatr Blood Cancer 2008, 50: 1159-62. [PMID: 17973315]
  2. Loncarevic IF, Hering A, Posorski N, Linden T, Hoyer H, Bucsky P: Number of genomic imbalances correlates with the overall survival for adrenocortical cancer in childhood. Pediatr Blood Cancer 2008, 51: 356-62. [PMID: 18478573]
  3. Hering A, Michel S, Ernst G, Claussen U, Kloetzer Ch, Parlowsky T, Bucsky P, Loncarevic IF: Characteristic chromosomal imbalances in pediatric pheochromocytoma. Genes Chromosomes and Cancer (accepted paper)
  4. Linden T, Oommen PT, Ueck B, Bucsky P: Paediatric adrenocortical carcinoma: preliminary results of the multicentre therapy study on malignant endocrine tumours GPOH-MET 97. Pediatric Blood & Cancer 2005, 482 P. D. 112
  5. Seyyedi S, Parlowsky T, Bucsky P : Interimsanalyse der interdisziplinären multizentrischen Therapieoptimierungsstudie im Kindes- und Jugendalter, GPOH-MET 97. Monatsschr. Kinderheilk 2002, 150: 1303-1304.
  6. Oommen PT, Linden T, Romahn A, Bucsky P: UICC-2002 TNM-classification is not suitable for differentiated thyroid carcinoma in children and adolescent - interim results of GPOH-MET 97 trial. Pediatric Blood & Cancer 2005, 45: 482 P.D. 111
  7. Parlowsky T, Bucsky P: Aktueller Stand der interdisziplinären multizentrischen Therapiestudie "Maligne endokrine Tumoren im Kindes- und Jugendalter - GPOH-MET 97". Monatsschr. Kinderheilkd 2000, 148: 971 Abstr.

Literature on Langerhans Cell Histiocytosis (LCH)

Search PubMed for recently published articles (external information service)
  1. Lehrnbecher T, Salzmann-Manrique E, Soerensen J, Beutel K, Janka G, Gadner H, Minkov M: Variant alleles of cytokine genes influence risk and clinical course of Langerhans cell histiocytosis. British journal of haematology 2011,Epub ahead of print [PMID: 21848890]
  2. Minkov M, Steiner M, Pötschger U, Aricò M, Braier J, Donadieu J, Grois N, Henter JI, Janka G, McClain K, Weitzman S, Windebank K, Ladisch S, Gadner H, International LCH Study Group: Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. The Journal of pediatrics 2008, 153: 700-5, 705.e1 [PMID: 18589441]
  3. Minkov M, Pötschger U, Grois N, Gadner H, Dworzak MN: Bone marrow assessment in Langerhans cell histiocytosis. Pediatric blood & cancer 2007, 49: 694 [PMID: 17455318]
  4. Minkov M, Prosch H, Steiner M, Grois N, Pötschger U, Kaatsch P, Janka-Schaub G, Gadner H: Langerhans cell histiocytosis in neonates. Pediatric blood & cancer 2005, 45: 802 [PMID: 15770639]
  5. Prosch H, Grois N, Prayer D, Waldhauser F, Steiner M, Minkov M, Gadner H: Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis. Pediatric blood & cancer 2004, 43: 594 [PMID: 15382278]
  6. Minkov M, Grois N, Heitger A, Pötschger U, Westermeier T, Gadner H, DAL-HX Study Group: Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Medical and pediatric oncology 2002, 39: 581 [PMID: 12376981]
  7. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, Komp D, Michaelis J, Nicholson S, Pötschger U, Pritchard J, Ladisch S, Histiocyte Society: A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. The Journal of pediatrics 2001, 138: 728 [PMID: 11343051]
  8. Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H: Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Medical and pediatric oncology 2001, 37: 108 [PMID: 11496348]
  9. Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H: Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol 2001, 37: 108 [PMID: 11496348]
  10. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, Komp D, Michaelis J, Nicholson S, Potschger U, Pritchard J, Ladisch S: A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001, 138: 728 [PMID: 11343051]
  11. Gadner H: Langerhans' cell histiocytosis - still an unsolved problem editorial. Pediatr Hematol Oncol 1999, 16: 489 [PMID: 10599086]

Other rare tumours

  1. Brecht IB, Schneider DT, Klöppel G, von Schweinitz D, Barthlen W, Hamre MR: Malignant Pancreatic Tumors in Children and Young Adults: Evaluation of 228 Patients Identified through the Surveillance, Epidemiology, and End Result (SEER) Database. Klinische Padiatrie 2011,Epub ahead of print [PMID: 22012608]
  2. Distelmaier F, Calaminus G, Harms D, Sträter R, Kordes U, Fleischhack G, Göbel U, Schneider DT: Ovarian small cell carcinoma of the hypercalcemic type in children and adolescents: a prognostically unfavorable but curable disease. Cancer 2006, 107: 2298 [PMID: 16998935]
  3. Schneider DT, Jänig U, Calaminus G, Göbel U, Harms D: Ovarian sex cord-stromal tumors--a clinicopathological study of 72 cases from the Kiel Pediatric Tumor Registry. Virchows Archiv : an international journal of pathology 2003, 443: 549 [PMID: 12910419]

Haematological diseases

Literature on Diamond Blackfan Anaemia (DBA) trials

Search PubMed for recently published articles (external information service)
  1. Faivre L, Meerpohl J, Da Costa L, Marie I, Nouvel C, Gnekow A, Bender-Gotze C, Bauters F, Coiffier B, Peaud, PY, Rispal P, Berrebi A, Berger C, Flesch M, Sagot P, Varet B, Niemeyer C, Tchernia G, Leblanc, T: High-risk pregnancies in Diamond-Blackfan anemia: a survey of 64 pregnancies from the French and German registries. Haematologica 2006, 91: 530-3. Epub 2006 Mar 15. [PMID: 16537118]
  2. Gazda, HT, Grabowska A, Merida-Long, LB, Latawiec E, Schneider, HE, Lipton, JM, Vlachos A, Atsidaftos E, Ball, SE, Orfali, KA, Niewiadomska E, Da Costa L, Tchernia G, Niemeyer C, Meerpohl, JJ, Stahl J, Schratt G, Glader B, Backer K, Wong C, Nathan, DG, Beggs, AH, Sieff, CA: Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am.J Hum.Genet 2006, 79: 1110-8. Epub 2006 Nov 2. [PMID: 17186470]
  3. Gazda, HT, Zhong R, Long L, Niewiadomska E, Lipton, JM, Ploszynska A, Zaucha, JM, Vlachos A, Atsidaftos E, Viskochil, DH, Niemeyer, CM, Meerpohl, JJ, Rokicka-Milewska R, Pospisilova D, Wiktor-Jedrzejczak W, Nathan, DG, Beggs, AH, Sieff, CA: RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations. Br J Haematol 2004, 127: 105 [PMID: 15384984]
  4. Da Costa L, Tchernia G, Gascard P, Lo A, Meerpohl J, Niemeyer C, Chasis, JA, Fixler J, Mohandas, N: Nucleolar localization of RPS19 protein in normal cells and mislocalization due to mutations in the nucleolar localization signals in 2 Diamond-Blackfan anemia patients: potential insights into pathophysiology. Blood 2003, 101: 5039-45. Epub 2003 Feb 13. [PMID: 12586610]

Immunological diseases

Literature on haemophagocytic lymphohistiocytosis (HLH) trials

Search PubMed for recently published articles (external information service)
  1. Janka GE: Hemophagocytic syndromes. Blood reviews 2007, 21: 245 [PMID: 17590250]
  2. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric blood & cancer 2007, 48: 124 [PMID: 16937360]
  3. Janka GE: Familial and acquired hemophagocytic lymphohistiocytosis. European journal of pediatrics 2007, 166: 95 [PMID: 17151879]
  4. Ouachée-Chardin M, Elie C, de Saint Basile G, Le Deist F, Mahlaoui N, Picard C, Neven B, Casanova JL, Tardieu M, Cavazzana-Calvo M, Blanche S, Fischer A: Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 2006, 117:e743 [PMID: 16549504]
  5. Filipovich AH: Life-threatening hemophagocytic syndromes: current outcomes with hematopoietic stem cell transplantation. Pediatric transplantation 2005, 9 Suppl 7: 87 [PMID: 16305623]
  6. Imashuku S, Kuriyama K, Sakai R, Nakao Y, Masuda S, Yasuda N, Kawano F, Yakushijin K, Miyagawa A, Nakao T, Teramura T, Tabata Y, Morimoto A, Hibi S: Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Medical and pediatric oncology 2003, 41: 103 [PMID: 12825212]
  7. Henter JI, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G, Histocyte Society: Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002, 100: 2367 [PMID: 12239144]
  8. Imashuku S: Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Critical reviews in oncology/hematology 2002, 44: 259 [PMID: 12467966]
  9. Dürken M, Finckenstein FG, Janka GE: Bone marrow transplantation in hemophagocytic lymphohistiocytosis. Leukemia & lymphoma 2001, 41(1-2): 89 [PMID: 11342360]
  10. Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, Sako M, Hibi S: Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001, 19: 2665 [PMID: 11352958]
  11. Baker KS, DeLaat CA, Steinbuch M, Gross TG, Shapiro RS, Loechelt B, Harris R, Filipovich AH: Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood 1997, 89: 3857 [PMID: 9160694]
  12. Henter J, Arico M, Egeler R, Elinder G, Favara B, Filipovich A, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D: HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 1997, 28: 342 [PMID: 9121398]
  13. Blanche S, Caniglia M, Girault D, Landman J, Griscelli C, Fischer A: Treatment of hemophagocytic lymphohistiocytosis with chemotherapy and bone marrow transplantation: a single-center study of 22 cases. Blood 1991, 78: 51 [PMID: 2070059]
  14. Henter JI, Elinder G, Ost A: Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Seminars in oncology 1991, 18: 29 [PMID: 1992521]

German Children's Cancer Registry

Publications from the German Children's Cancer Registry

Search PubMed for recently published articles (external information service)
  1. Grabow D, Lacher C, Kaatsch P: Former childhood cancer patients need a competent help desk. Klin padiatr 2011, 223: 187 [PMID: 21462098]
  2. Queißer-Luft A, Wiesel A, Stolz G, Mergenthaler A, Kaiser M, Schlaefer K, Wahrendorf J, Blettner M, Spix C: Birth defects in the vicinity of nuclear power plants in Germany. Radiat Environ Biophys 2011 [Epub ahead of print] [PMID: 21213111]
  3. Grabow D, Spix C, Blettner M, Kaatsch P: Strategy for long-term surveillance at the German Childhood Cancer Registry - an update. Klin padiatr 2011, 223: 159 [PMID: 21472636]
  4. Kaatsch P, Scheidemann-Wesp U, Schüz J: Maternal use of antibiotics and cancer in the offspring: results of a case-control study in Germany. Cancer causes & control 2010 [PMID: 20390445]
  5. Hug K, Grize L, Seidler A, Kaatsch P, Schüz J: Parental occupational exposure to extremely low frequency magnetic fields and childhood cancer: a German case-control study. American journal of epidemiology 2010, 171: 27 [PMID: 19942577]
  6. Spix C, Mergenthaler A, Kaatsch P: [Data exchange between the German Childhood Cancer Registry and the Epidemiological Cancer State Registries]. Klinische Padiatrie 2009, 221: 398 [PMID: 19890798]
  7. Weihkopf T, Blettner M, Dantonello T, Jung I, Klingebiel T, Koscielniak E, Lückel M, Spix C, Kaatsch P: Incidence and time trends of soft tissue sarcomas in German children 1985-2004 - a report from the population-based German Childhood Cancer Registry. European journal of cancer 2008, 44: 432 [PMID: 18077150]
  8. Laengler A, Spix C, Seifert G, Gottschling S, Graf N, Kaatsch P: Complementary and alternative treatment methods in children with cancer: A population-based retrospective survey on the prevalence of use in Germany. European journal of cancer 2008, 44: 2233 [PMID: 18809313]
  9. Pommerening K, Debling D, Kaatsch P, Blettner M: [Registries for rare diseases. Compliance and data protection]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2008, 51: 491 [PMID: 18696140]
  10. Debling D, Spix C, Blettner M, Michaelis J, Kaatsch P: The cohort of long-term survivors at the German childhood cancer registry. Klinische Padiatrie 2008, 220: 371 [PMID: 18949673]
  11. Kaatsch P, Spix C, Schulze-Rath R, Schmiedel S, Blettner M: Leukaemia in young children living in the vicinity of German nuclear power plants. International journal of cancer. Journal international du cancer 2008, 122: 721 [PMID: 18067131]
  12. Kaatsch P: 25 Jahre Deutsches Kinderkrebsregister: Langzeitfolgen rücken ins Blickfeld - Nehmen Krebserkrankungen bei Kindern zu? WIR-Informationsschrift von DLFH-Dachverband und Aktion für krebskranke Kinder e.V. (Bonn) 2005, 3 [URI: http://www.kinderkrebsstiftung.de/fileadmin/KKS/files/zeitschriftWIR/2005_3/langzeitfolgen01.pdf]
  13. Kaatsch P, Spix C, Schüz J: Epidemiologie, Ätiologie, Prävention. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J (Hrsg): Pädiatrische Hämatologie und Onkologie, S. 421-35 Springer Medizin Verlag Heidelberg. 2005
  14. Schüz J, Blettner M, Michaelis J, Kaatsch P : Ursachen von Leukämien im Kindesalter: Resümee einer Fallkontrollstudie des Deutschen Kinderkrebsregisters. Dtsch Arztebl 102: A2557-64, 2005.
  15. Kaatsch P: Deutsches Kinderkrebsregister - Eine international angesehene Datenquelle. Dtsch Arztebl 102: A1421-22, 2005
  16. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh JW, ACCIS Scientific Committee: Trends in childhood cancer incidence in Europe, 1970-99. Lancet 2005, 365: 2088 [PMID: 15964441]
  17. Kaatsch P, Blettner M, Spix C, Jürgens H: Follow up of long-term survivors after childhood cancer in Germany. Klinische Pädiatrie 2005, 217: 169 [PMID: 15858709]
  18. Längler A, Herold R, Kaatsch P, Souchon R, Tautz C: Kinder sind keine kleine Erwachsenen (Teil 1: Allgemeine Grundlagen der pädiatrischen Onkologie). Klinikarzt 34: 159-64, 2005
  19. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M, EUROCARE Working Group: Childhood cancer survival trends in Europe: a EUROCARE Working Group study. Journal of clinical oncology 2005, 23: 3742 [PMID: 15923571]
  20. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P: International Classification of Childhood Cancer, third edition. Cancer 2005, 103: 1457 [PMID: 15712273]
  21. Greten TF, Manns MP, Reinisch I, Kaatsch P: Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. Gut 2005, 54: 732 [PMID: 15831932]
  22. Längler A, Spix C, Jung I, Kaatsch P: Comlementary and alternative medicine (CAM) in Pediatric oncology- results of a nationwide parents-questionnaire on frequency of CAM-use. 37th SIOP Congress, Vancouver, Canada 2005
  23. Klein G, Michaelis J, Spix C, Wibbing R, Eggers G, Ritter J, Kaatsch P: Second malignant neoplasms after treatment of childhood cancer. Eur J Cancer 2003, 39: 808 [PMID: 12651207]

Long-term side effects

Literature on long-term side effects

Search PubMed for recently published articles (external information service)
  1. Paulides M, Stöhr W, Laws HJ, Graf N, Lakomek M, Berthold F, Schmitt K, Niggli F, Jürgens H, Bielack S, Koscielniak E, Klingebiel T, Langer T: Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: a report from the Late Effects Surveillance System. Vaccine 2011, 11; 29: 1565 [PMID: 21219980]
  2. Paulides M, Stöhr W, Laws HJ, Graf N, Lakomek M, Berthold F, Schmitt K, Niggli F, Jürgens H, Bielack S, Koscielniak E, Klingebiel T, Langer T: Immunity against tetanus and diphtheria after childhood sarcoma treatment. Klinische Padiatrie 2010, 222: 196 [PMID: 20514629]
  3. Bölling T, Ernst I, Pape H, Martini C, Rübe C, Timmermann B, Fischedick K, Kortmann RD, Willich N: Dose-Volume Analysis of Radiation Nephropathy in Children: Preliminary Report of the RiSK Consortium. International journal of radiation oncology, biology, physics 2010 Jul 15; [PMID: 20638187]
  4. Selo N, Bölling T, Ernst I, Pape H, Martini C, Rübe C, Timmermann B, Fischedick K, Kortmann RD, Gerss J, Koch R, Willich N: Acute toxicity profile of radiotherapy in 690 children and adolescents: RiSK data. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010, 97: 119 [PMID: 20605649]
  5. Peeters J, Meitert J, Paulides M, Wiener A, Beck JD, Calaminus G, Langer T: Health-related quality of life (HRQL) in all-patients treated with chemotherapy only: a report from the late effects surveillance system in Germany. Klinische Padiatrie 2009, 221: 156 [PMID: 19437363]
  6. Peeters J, Meitert J, Paulides M, Beck JD, Langer T: Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009. Strahlentherapie und Onkologie 2009, 185 Suppl 2: 5 [PMID: 19685025]
  7. Langer T, Stöhr W, Paulides M, Kremers A, Dorr HG, Göbel U, Beck JD: Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klinische Pädiatrie 2005, 217: 176 [PMID: 15858710]
  8. Langer T, Dörr HG, Bielack S, Jürgens H, Göbel U, Willich N and Beck JD: Spätfolgen in der Nachsorge von krebskranken Kindern und Jugendlichen. Der Onkologe 2005, 11: 1101 [DOI: 10.1007/s00761-005-0933-2]
  9. Stohr W, Paulides M, Brecht I, Kremers A, Treuner J, Langer T, Beck JD: Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS). Journal of cancer research and clinical oncology 2006, 132: 35 [PMID: 16205946]
  10. Burger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M: Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. Pediatric blood & cancer 2005, 44: 220 [PMID: 15514916]
  11. Paulides M, Stöhr W, Bielack S, Jürgens H, Treuner J, Schuck A, Willich N, Sauer R, Dörr, HG, Rascher W, Langer T, Beck, JD: Major sequelae of antineoplastic therapy prospectively evaluated in 162 relapse-free adult sarcoma patients. Onkologie 2005, 28;S3; 56

 
KPOH Logo     Logo GPOH      Logo Deutsche Kinderkrebsstiftung       HONcode accreditation seal